Cyclosporin A
Based on 213 publication(s) in Google Scholar
Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.90%
- CAS No.: 59865-13-3
- Formule: C62H111N11O12
- Masse moléculaire:1202.61
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Cyclosporin A
More- Signal Transduct Target Ther. 2026 Jun 10;11(1):226. [Abstract]
- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Science. 2026 Jul 2;393(6806):eaef0825. [Abstract]
- Cell Metab. 2026 Jul 7;38(7):1367-1384.e9. [Abstract]
- Cell Res. 2026 Jan 9. [Abstract]
- Nat Metab. 2023 Mar;5(3):481-494. [Abstract]
- Bioact Mater. 2025 Feb 12:46:569-581. [Abstract]
- Bioact Mater. 2025 Feb 13:48:55-70. [Abstract]
- Bioact Mater. 2023 Mar 29:27:125-137. [Abstract]
- Bioact Mater. 2022 Nov 23:23:300-313. [Abstract]
- Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]
- Autophagy. 2026 May 31:1-22. [Abstract]
- Autophagy. 2026 Mar 15:1-22. [Abstract]
- Protein Cell. 2025 Dec 8:pwaf109. [Abstract]
- Nat Commun. 2025 Aug 26;16(1):7954. [Abstract]
- Nat Commun. 2025 May 10;16(1):4365. [Abstract]
- Nat Commun. 2024 Aug 6;15(1):6685. [Abstract]
- Nat Commun. 2021 May 18;12(1):2915. [Abstract]
- Exp Mol Med. 2022 Feb;54(2):129-142. [Abstract]
- ACS Nano. 2025 Nov 25;19(46):39667-39681. [Abstract]
- J Adv Res. 2026 Mar 12:S2090-1232(26)00239-0. [Abstract]
- Redox Biol. 2026 Jun 27:95:104280. [Abstract]
- Redox Biol. 2025 Aug 5:86:103806. [Abstract]
- Redox Biol. 2023 Nov:67:102887. [Abstract]
- Redox Biol. 2022 Aug;54:102355. [Abstract]
- J Nanobiotechnology. 2026 Apr 2;24(1):431. [Abstract]
- Theranostics. 2024 Jan 1;14(1):116-132. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Adv Sci (Weinh). 2025 Dec 5:e20444. [Abstract]
- Adv Sci (Weinh). 2025 Aug 19:e05666. [Abstract]
- Adv Sci (Weinh). 2024 Jun 20:e2404171. [Abstract]
- Adv Sci (Weinh). 2023 Apr;10(12):e2201164. [Abstract]
- Adv Sci (Weinh). 2023 Mar;10(7):e2203869. [Abstract]
- Adv Sci (Weinh). 2021 Jan 6;8(5):2002738. [Abstract]
- Sci Adv. 2023 Feb 10;9(6):eade8829. [Abstract]
- Cell Death Differ. 2026 Jun 24. [Abstract]
- Research (Wash D C). 2026 Apr 14:9:1232. [Abstract]
- Research (Wash D C). 2026 Apr 15:9:1235. [Abstract]
- Pharmacol Res. 2026 May:227:108177. [Abstract]
- Cell Death Dis. 2026 Mar 26;17(1):381. [Abstract]
- Cell Death Dis. 2026 Feb 10;17(1):213. [Abstract]
- Pharmacol Res. 2023 Sep:195:106881. [Abstract]
- Cell Death Dis. 2021 Apr 1;12(4):336. [Abstract]
- Cell Death Dis. 2021 Apr 20;12(5):413. [Abstract]
- Cell Death Dis. 2018 May 22;9(6):598. [Abstract]
- Environ Sci Technol. 2017 Dec 5;51(23):13938-13948. [Abstract]
- Cell Commun Signal. 2025 Dec 24;24(1):50. [Abstract]
- Cell Commun Signal. 2024 Jul 18;22(1):366. [Abstract]
- Phytomedicine. 2025 Oct 11:148:157402. [Abstract]
- Adv Healthc Mater. 2026 Jul;15(26):e71343. [Abstract]
- Mater Today Bio. 2026 Jun 13:39:103349. [Abstract]
- Mater Today Bio. 2026 Jun 8:38:103324. [Abstract]
- Appl Phys Rev. 2026 Jan 21.
- Acta Pharmacol Sin. 2025 Feb;46(2):430-447. [Abstract]
- Arthritis Rheumatol. 2023 Feb;75(2):305-317. [Abstract]
- Biomater Res. 2025 Nov 7:29:0280. [Abstract]
- J Transl Med. 2025 Nov 14;23(1):1289. [Abstract]
- J Transl Med. 2024 Aug 28;22(1):796. [Abstract]
- Sci China Life Sci. 2025 Aug 22. [Abstract]
- Aging Dis. 2022 Oct 1;13(5):1546-1561. [Abstract]
- Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2009539118. [Abstract]
- Oncogene. 2024 Nov;43(49):3570-3585. [Abstract]
- Cell Chem Biol. 2022 Sep 15;29(9):1368-1380.e5. [Abstract]
- Int J Biol Macromol. 2020 May 1;150:261-280. [Abstract]
- Int J Mol Med. 2026 Jan;57(1):22. [Abstract]
- Neural Regen Res. 2023 Apr;18(4):849-855. [Abstract]
- Int J Mol Med. 2020 Aug;46(2):663-674. [Abstract]
- EMBO J. 2023 Aug 15;42(16):e113258. [Abstract]
- Antioxidants (Basel). 2023 Dec 16;12(12):2123. [Abstract]
- Antioxidants (Basel). 2022 Jul 26;11(8):1455. [Abstract]
- Free Radic Biol Med. 2026 Jul:250:436-452. [Abstract]
- Free Radic Biol Med. 2025 Dec 18:244:422-434. [Abstract]
- Free Radic Biol Med. 2025 Dec 16:244:380-394. [Abstract]
- Free Radic Biol Med. 2025 Nov 11:243:111-125. [Abstract]
- Free Radic Biol Med. 2025 Oct 25.
- Free Radic Biol Med. 2025 Aug 8:240:15-28. [Abstract]
- Free Radic Biol Med. 2024 Nov 20:225:665-676. [Abstract]
- Free Radic Biol Med. 2023 Nov 1:208:319-333. [Abstract]
- Int J Pharm X. 2024 Nov 4:8:100300. [Abstract]
- Clin Transl Med. 2022 Aug;12(8):e1002. [Abstract]
- Stem Cell Res Ther. 2025 Oct 29;16(1):593. [Abstract]
- Cell Rep. 2026 Jun 25;45(7):117616. [Abstract]
- Cell Rep. 2026 Jun 9;45(6):117515. [Abstract]
- Cell Rep. 2025 Dec 10;44(12):116673. [Abstract]
- Cell Rep. 2022 Mar 8;38(10):110486. [Abstract]
- Cell Rep. 2021 Nov 30;37(9):110069. [Abstract]
- Cell Rep. 2021 Jul 20;36(3):109398. [Abstract]
- Cell Prolif. 2024 Jul 3:e13704. [Abstract]
- Br J Pharmacol. 2025 Aug;182(16):3923-3951. [Abstract]
- Br J Pharmacol. 2021 Jun;178(11):2305-2323. [Abstract]
- Chin Med. 2025 Mar 25;20(1):41. [Abstract]
- J Med Chem. 2025 Oct 23;68(20):21394-21411. [Abstract]
- J Invest Dermatol. 2023 May;143(5):722-730.e1. [Abstract]
- Redox Rep. 2026 Dec;31(1):2622255. [Abstract]
- J Ethnopharmacol. 2024 Jun 13:118456. [Abstract]
- J Agric Food Chem. 2024 Jun 12;72(23):13039-13053. [Abstract]
- J Agric Food Chem. 2023 Oct 25;71(42):15809-15820. [Abstract]
- J Agric Food Chem. 2023 May 10;71(18):7032-7045. [Abstract]
- Ecotoxicol Environ Saf. 2020 Oct 1;202:110901. [Abstract]
- Biochem Pharmacol. 2023 Oct:216:115796. [Abstract]
- Biochem Pharmacol. 2022 Sep:203:115164. [Abstract]
- Biochem Pharmacol. 2022 Aug:202:115116. [Abstract]
- Biochem Pharmacol. 2022 Mar:197:114904. [Abstract]
- Life Sci. 2026 Apr 15:391:124281. [Abstract]
- Life Sci. 2020 Nov 15;261:118351. [Abstract]
- Inflamm Res. 2024 Jun;73(6):945-960. [Abstract]
- J Mol Cell Biol. 2024 Jul 1;16(1):mjad080. [Abstract]
- Neurobiol Dis. 2019 Sep:129:44-55. [Abstract]
- Colloids Surf B Biointerfaces. 2025 Oct 9:257:115197. [Abstract]
- Commun Biol. 2025 Jul 29;8(1):1118. [Abstract]
- Front Microbiol. 2024 Jul 30:15:1450557. [Abstract]
- J Inflamm. 2024 Apr 19;21(1):11. [Abstract]
- Eur J Pharmacol. 2025 Oct 15:1005:178118. [Abstract]
- Eur J Pharmacol. 2021 Dec 5:912:174617. [Abstract]
- Int J Mol Sci. 2023 Feb 16;24(4):4022. [Abstract]
- Int J Mol Sci. 2022 Dec 25;24(1):343. [Abstract]
- Int Immunopharmacol. 2018 Sep:62:67-76. [Abstract]
- Phenomics. 2026 May 25.
- Mol Neurobiol. 2025 Jun 6. [Abstract]
- Mol Neurobiol. 2025 Jan;62(1):445-460. [Abstract]
- Am J Respir Cell Mol Biol. 2022 Apr;66(4):382-390. [Abstract]
- Front Pharmacol. 2021 Oct 15;12:733805. [Abstract]
- Am J Respir Cell Mol Biol. 2019 Sep;61(3):355-366. [Abstract]
- Chem Biol Interact. 2026 Jun 1:432:112047. [Abstract]
- Toxicology. 2025 Jun 3:154210. [Abstract]
- Chem Biol Interact. 2025 May 8:111525. [Abstract]
- J Thromb Haemost. 2023 May;21(5):1322-1335. [Abstract]
- Toxicology. 2023 Mar 15:487:153466. [Abstract]
- Chem Biol Interact. 2022 Aug 25:363:110003. [Abstract]
- Bioorg Chem. 2022 Jun;123:105779. [Abstract]
- Sci Rep. 2025 Jul 1;15(1):22327. [Abstract]
- Toxics. 2025 Apr 23;13(5):332. [Abstract]
- PLoS Pathog. 2024 Dec 2;20(12):e1012737. [Abstract]
- J Dairy Sci. 2025 Aug;108(8):7896-7911. [Abstract]
- Cell Signal. 2025 Mar 25:111765. [Abstract]
- Mol Cell Biochem. 2025 May;480(5):3079-3095. [Abstract]
- J Cell Mol Med. 2024 Oct;28(20):e70151. [Abstract]
- J Physiol. 2026 Feb 26. [Abstract]
- J Neurochem. 2022 Jan;160(1):51-63. [Abstract]
- Brain Res Bull. 2025 Jan 16:111214. [Abstract]
- iScience. 2024 Aug 22;27(10):110784. [Abstract]
- Brain Res Bull. 2023 Oct 1:202:110760. [Abstract]
- Acta Biochim Biophys Sin (Shanghai). 2022 Jan 25;54(1):64-76. [Abstract]
- ACS Chem Neurosci. 2021 Oct 6;12(19):3550-3557. [Abstract]
- FASEB J. 2026 Mar 31;40(6):e71636. [Abstract]
- FASEB J. 2025 Dec 31;39(24):e71322. [Abstract]
- FEBS J. 2025 Apr 22. [Abstract]
- J Virol. 2024 Nov 19;98(11):e0094724. [Abstract]
- Virol J. 2025 Apr 16;22(1):101. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar;398(3):3001-3014. [Abstract]
- J Immunol. 2022 Apr 1;208(7):1616-1631. [Abstract]
- J Immunol. 2020 Feb 1;204(3):569-585. [Abstract]
- Toxins. 2019 Jun 18;11(6):349. [Abstract]
- J Funct Foods. 2024 Aug.
- Neurotox Res. 2021 Jun;39(3):740-753. [Abstract]
- Vet Res. 2026 Jun 13;57(1):107. [Abstract]
- ESC Heart Fail. 2026 May 5;13(3):xvag118. [Abstract]
- Viruses. 2020 Jun 10;12(6):628. [Abstract]
- Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158531. [Abstract]
- Mol Immunol. 2025 Oct:186:48-62. [Abstract]
- Drug Metab Dispos. 2025 Nov;53(11):100172. [Abstract]
- Drug Metab Dispos. 2025 Jul 29;53(9):100136. [Abstract]
- Drug Metab Dispos. 2025 Mar;53(3):100046. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- J Radiat Res Appl Sci. 2026 Feb 24.
- Exp Cell Res. 2024 Jul 31;441(2):114182. [Abstract]
- Arch Biochem Biophys. 2023 Jul 15:743:109644. [Abstract]
- J Neurooncol. 2025 Mar;172(1):163-173. [Abstract]
- Phytochemistry. 2021 Jul:187:112780. [Abstract]
- Neuroscience. 2026 Jun 6:610:122-135. [Abstract]
- Int J Cardiol. 2025 Dec 1:440:133681. [Abstract]
- Food Chem Toxicol. 2024 Apr:186:114522. [Abstract]
- Food Chem Toxicol. 2022 Feb:160:112811. [Abstract]
- Kaohsiung J Med Sci. 2025 Nov 5:e70131. [Abstract]
- BMC Cardiovasc Disord. 2023 Sep 21;23(1):474. [Abstract]
- Placenta. 2022 Jan:117:95-108. [Abstract]
- Cell Biochem Biophys. 2025 Jun;83(2):1565-1573. [Abstract]
- Vet Microbiol. 2026 Aug:319:111069. [Abstract]
- Toxicol In Vitro. 2022 Apr:80:105324. [Abstract]
- Biochem Biophys Res Commun. 2019 Apr 30;512(2):269-275. [Abstract]
- Biochem Biophys Res Commun. 2018 Sep 3;503(1):297-303. [Abstract]
- J Viral Hepat. 2026 Jan;33(1):e70118. [Abstract]
- Exp Ther Med. 2022 Nov 8;24(6):750. [Abstract]
- Biopharm Drug Dispos. 2022 Dec;43(6):265-271. [Abstract]
- Genes Genomics. 2022 Dec;44(12):1593-1605. [Abstract]
- Connect Tissue Res. 2026 May;67(3):243-257. [Abstract]
- Biochem Genet. 2024 Dec 26. [Abstract]
- Am J Transl Res. 2018 Aug 15;10(8):2435-2444. [Abstract]
- Acta Cir Bras. 2022 Jun 15;37(3):e370305. [Abstract]
- STAR Protoc. 2022 Jun 4;3(2):101423. [Abstract]
- Mol Cell Toxicol (2019) 15:209-219
- bioRxiv. 2026 Jun 12:2026.06.11.731694. [Abstract]
- bioRxiv. 2026 May 29:2026.05.26.727520. [Abstract]
- Res Sq. 2025 Oct 6.
- bioRxiv. 2025 May 16.
- SSRN. 2025 Mar 31.
- Sci Total Environ. 2024 Jun 30:946:174246. [Abstract]
- Elife. 2023 Dec 6:12:RP88874. [Abstract]
- Research Square Preprint. 2024 Apr 19.
- Research Square Preprint. 2023 Sep 19.
- bioRxiv. 2023 Jun 6.
- Research Square Preprint. 2023 Jun 8.
- Chemosphere. 2023 May:323:138249. [Abstract]
- Research Square Print. 2023 Feb 14.
- Oxid Med Cell Longev. 2022 Sep 1;2022:4722647. [Abstract]
- Research (Wash D C). 2022 Aug 3:2022:9832128. [Abstract]
- Biomed Pharmacother. 2022 May 10;151:113092. [Abstract]
- Front Med. 2021 Jun;15(3):472-485. [Abstract]
- Ann Transl Med. 2020 Jul;8(14):858. [Abstract]
- bioRxiv. 2020 Jun.
- Tianjin Med J. 2018, 46(9): 932-936.
- Am J Dig Dis (Madison). 2015;2(2):95-99.
- J Clin Toxicol 2014, 4:5
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
IF
-
WB
Voir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform Cyclophilin
More
Activité biologique
|
Cyclophilin D |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 2008 | IC50 |
4.78 μM
Compound: cyclosporin A
|
Inhibition of human MRP1 in human 2008 cells
Inhibition of human MRP1 in human 2008 cells
|
[PMID: 18707884] |
| 2008 | IC50 |
2.81 μM
Compound: CsA
|
Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay
Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay
|
[PMID: 23851114] |
| 2008 | IC50 |
2.7 μM
Compound: Cyclosporine A
|
Inhibition of MRP1 in human 2008 cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay
Inhibition of MRP1 in human 2008 cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay
|
[PMID: 24184213] |
| A2780 | IC50 |
4.92 μM
Compound: cyclosporin A
|
Inhibition of P-gp in human A2780 cells
Inhibition of P-gp in human A2780 cells
|
[PMID: 18707884] |
| A2780 | GI50 |
8.94 μM
Compound: Cyclosporine A
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27100033] |
| A2780 ADR | IC50 |
1.4 μM
Compound: Cyclosporin A
|
Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay
Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay
|
[PMID: 19250834] |
| A2780 ADR | IC50 |
0.99 μM
Compound: CsA
|
Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay
Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay
|
[PMID: 23851114] |
| A2780 ADR | IC50 |
0.92 μM
Compound: Cyclosporine A
|
Inhibition of MDR1 in human doxorubicin-resistant A2780adr cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay
Inhibition of MDR1 in human doxorubicin-resistant A2780adr cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay
|
[PMID: 24184213] |
| A2780 ADR | IC50 |
0.919 μM
Compound: CsA
|
Inhibition of ABCB1 in human A2780adr cells pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay
Inhibition of ABCB1 in human A2780adr cells pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay
|
[PMID: 25855895] |
| A2780 ADR | GI50 |
8.63 μM
Compound: Cyclosporine A
|
Cytotoxicity against human A2780/ADR cells overexpressing ABCB1 assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human A2780/ADR cells overexpressing ABCB1 assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 27100033] |
| A2780 ADR | IC50 |
1.41 μM
Compound: Cyclosporine A
|
Inhibition of ABCB1 in human A2780/ADR cells incubated for 30 mins measured up to 3600 secs with time intervals of 60 secs by calcein accumulation assay
Inhibition of ABCB1 in human A2780/ADR cells incubated for 30 mins measured up to 3600 secs with time intervals of 60 secs by calcein accumulation assay
|
[PMID: 27100033] |
| A2780 ADR | IC50 |
1.21 μM
Compound: Cyclosporine A
|
Inhibition of ABCB1 in human A2780/ADR cells assessed as reduction in calcien-AM efflux preincubated for 30 mins followed by calcien-AM addition measured immediately at 60 sec time interval for 60 mins by fluorescence assay
Inhibition of ABCB1 in human A2780/ADR cells assessed as reduction in calcien-AM efflux preincubated for 30 mins followed by calcien-AM addition measured immediately at 60 sec time interval for 60 mins by fluorescence assay
|
[PMID: 27676469] |
| B-cell | IC50 |
0.07 μg/mL
Compound: cyclosporin A
|
Immunosuppressive activity in BALB/c mouse splenic B lymphocytes assessed as inhibition of LPS-induced cell proliferation after 72 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse splenic B lymphocytes assessed as inhibition of LPS-induced cell proliferation after 72 hrs by MTT assay
|
[PMID: 14738397] |
| B-cell | IC50 |
0.159 μM
Compound: CsA
|
Inhibition of LPS-induced BALB/c mouse B cell proliferation
Inhibition of LPS-induced BALB/c mouse B cell proliferation
|
[PMID: 17081761] |
| B-cell | IC50 |
0.74 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in LPS-induced mouse B-lymphocytes proliferation incubated for 8 hrs by beta scintillation counting based [3H]thymidine incorporation assay
Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in LPS-induced mouse B-lymphocytes proliferation incubated for 8 hrs by beta scintillation counting based [3H]thymidine incorporation assay
|
[PMID: 35678710] |
| Breast cancer cell line | EC50 |
0.5 μM
Compound: Cyclosporin A
|
Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%.
Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%.
|
[PMID: 11784143] |
| Breast cancer cell line | EC50 |
0.6 μM
Compound: Cyclosporin A
|
Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%
Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%
|
[PMID: 11784143] |
| Caco-2 | IC50 |
1.3 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells
TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells
|
[PMID: 10820137] |
| Caco-2 | EC50 |
80 μM
Compound: cyclosporin A
|
Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells
Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells
|
[PMID: 17936633] |
| Caco-2 | EC50 |
80 μM
Compound: cyclosporin A
|
Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells
Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells
|
[PMID: 18257545] |
| Caco-2 | EC50 |
80 μM
Compound: cyclosporin A
|
Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells
Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells
|
[PMID: 18276145] |
| Caco-2 | EC50 |
45.5 μM
Compound: Cyclosporin A
|
Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells
Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells
|
[PMID: 18524592] |
| Caco-2 | IC50 |
2.9 μM
Compound: CsA
|
Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux
Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux
|
[PMID: 23382458] |
| Cancer cell lines | IC50 |
1 μM
Compound: Cyclosporin A
|
Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.
Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.
|
[PMID: 11784143] |
| Cancer cell lines | IC50 |
1.1 μM
Compound: Cyclosporin A
|
Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.
Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.
|
[PMID: 11784143] |
| CCRF-CEM | IC50 |
3.4 μM
Compound: 1
|
Inhibitory activity against Human MDR1 P-Glycoprotein ABC Transporter using leukemia CEM cells
Inhibitory activity against Human MDR1 P-Glycoprotein ABC Transporter using leukemia CEM cells
|
[PMID: 12361387] |
| CEM/VLB100 | IC50 |
3.41 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux (Calcein-AM: 0.25 uM) in CEM/VLB100 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux (Calcein-AM: 0.25 uM) in CEM/VLB100 cells
|
[PMID: 10891114] |
| EMT6 | IC50 |
440 nM
Compound: Cyclosporin A
|
Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0
Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0
|
[PMID: 10098671] |
| HEK293 | IC50 |
1.3 μM
Compound: Cyclosporin A
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
1.4 μM
Compound: Cyclosporin A
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
37 μM
Compound: Cyclosporin A
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
0.7 μM
Compound: Cyclosporine A
|
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate
|
[PMID: 22587986] |
| HEK293 | IC50 |
0.7 μM
Compound: Cyclosporine A
|
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate
|
[PMID: 22587986] |
| HEK293 | IC50 |
1.2 μM
Compound: Cyclosporine A
|
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate
|
[PMID: 22587986] |
| HeLa | IC50 |
1 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells
TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells
|
[PMID: 10565843] |
| HeLa | IC50 |
>8.3 μM
Compound: Cs
|
Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of viral replication
Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| HeLa | IC50 |
6.6 μM
Compound: Cs
|
Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 3 days
Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 3 days
|
[PMID: 18212100] |
| HepG2 | IC50 |
>50 μM
Compound: 92125416
|
HARVARD: Cytotoxicity in HepG2 cell line
HARVARD: Cytotoxicity in HepG2 cell line
|
[PMID: 22586124] |
| HepG2 | IC50 |
0.00165 μM
Compound: 92125416
|
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells
|
[PMID: 22586124] |
| HFF | IC50 |
>10000 nM
Compound: CSA
|
Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting
Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting
|
[PMID: 14593182] |
| HL-60 | IC50 |
>10 μM
Compound: 1
|
Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells
Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells
|
[PMID: 12361388] |
| Huh-5-2 | CC50 |
6 μM
Compound: Cyclosporine A
|
Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay
Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay
|
[PMID: 18625766] |
| Huh-5-2 | EC50 |
0.3 μM
Compound: Cyclosporine A
|
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay
Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay
|
[PMID: 18625766] |
| Huh-5-2 | CC50 |
4.4 μM
Compound: CsA
|
Cytostatic activity against human Huh5-2 cells assessed as decrease in cell proliferation after 3 days by MTS method
Cytostatic activity against human Huh5-2 cells assessed as decrease in cell proliferation after 3 days by MTS method
|
10.1039/C1MD00227A |
| Huh-5-2 | EC50 |
306 nM
Compound: CsA
|
Antiviral activity against Hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3'/5.1 subgenomic replicon infected in human Huh5-2 cells after 4 days by luciferase assay
Antiviral activity against Hepatitis C virus genotype 1b I389luc-ubi-neo/NS3-3'/5.1 subgenomic replicon infected in human Huh5-2 cells after 4 days by luciferase assay
|
10.1039/C1MD00227A |
| Huh-7 | CC50 |
5.62 μM
Compound: CsA
|
Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay
Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay
|
[PMID: 19933795] |
| Huh-7 | EC50 |
>10 μM
Compound: CsA
|
Antiviral activity against cyclosporine A/NIM-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay
Antiviral activity against cyclosporine A/NIM-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay
|
[PMID: 20176894] |
| Huh-7 | EC50 |
0.21 μM
Compound: CsA
|
Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay
Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay
|
[PMID: 20176894] |
| Huh-7 | EC50 |
3.39 μM
Compound: CsA
|
Antiviral activity against cyclosporine A-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay
Antiviral activity against cyclosporine A-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay
|
[PMID: 20176894] |
| Huh-7 | IC50 |
5810 nM
Compound: 1, CsA
|
Cytotoxicity against human HuH7 cells assessed as release of lactate dehydrogenase
Cytotoxicity against human HuH7 cells assessed as release of lactate dehydrogenase
|
[PMID: 20943390] |
| Huh-7 | EC50 |
137 nM
Compound: CsA
|
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis
Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis
|
10.1039/C1MD00227A |
| Huh-7 | EC50 |
198 nM
Compound: CsA
|
Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis
Antiviral activity against Hepatitis C virus genotype 1a H77 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis
|
10.1039/C1MD00227A |
| Huh-7 | EC50 |
455 nM
Compound: CsA
|
Antiviral activity against Hepatitis C virus genotype 2a JFH-1 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis
Antiviral activity against Hepatitis C virus genotype 2a JFH-1 infected in human Huh7 cells assessed as decrease in subgenomic RNA level after 72 hrs by RT-PCR analysis
|
10.1039/C1MD00227A |
| Jurkat | IC50 |
>10 μM
Compound: CsA
|
In vitro inhibition of Jurkat cell proliferation.
In vitro inhibition of Jurkat cell proliferation.
|
[PMID: 11384243] |
| Jurkat | IC50 |
>1 μM
Compound: cyclosporin-A
|
Inhibition of production of beta-galactosidase thymidine kinase RGA in Jurkat cells
Inhibition of production of beta-galactosidase thymidine kinase RGA in Jurkat cells
|
[PMID: 11881984] |
| Jurkat | IC50 |
0.007 μM
Compound: cyclosporin-A
|
Inhibition of production of IL-2 secretion in Jurkat cells
Inhibition of production of IL-2 secretion in Jurkat cells
|
[PMID: 11881984] |
| Jurkat | IC50 |
0.008 μM
Compound: cyclosporin-A
|
Inhibition of production of beta-galactosidase IL-2 RGA in Jurkat cells
Inhibition of production of beta-galactosidase IL-2 RGA in Jurkat cells
|
[PMID: 11881984] |
| Jurkat | IC50 |
2 nM
Compound: CsA
|
Immunosuppressive activity was measured by inhibition of the IL-2 production in Jurkat cells.
Immunosuppressive activity was measured by inhibition of the IL-2 production in Jurkat cells.
|
[PMID: 14643337] |
| Jurkat | EC50 |
0.005 μM
Compound: CsA
|
Antiinflammatory activity in human Jurkat cells assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay
Antiinflammatory activity in human Jurkat cells assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay
|
[PMID: 19933795] |
| Jurkat | EC50 |
6.7 nM
Compound: 1, CsA
|
Immunosuppressive activity against human Jurkat cells assessed as inhibition of phytohemagglutinin-M/phorbol myristate acetate-induced IL2 production
Immunosuppressive activity against human Jurkat cells assessed as inhibition of phytohemagglutinin-M/phorbol myristate acetate-induced IL2 production
|
[PMID: 20943390] |
| Jurkat | IC50 |
>10 μM
Compound: CsA
|
Cytotoxicity against human Jurkat cells after 4 days by MTT assay
Cytotoxicity against human Jurkat cells after 4 days by MTT assay
|
[PMID: 22984987] |
| Jurkat | IC50 |
1.4 nM
Compound: 1
|
Inhibition of NFAT activation in PMA/ionomycin-stimulated human Jurkat T cells incubated for 30 mins prior to PMA/ionomycin stimulation measured after 5 hrs by luciferase reporter gene assay
Inhibition of NFAT activation in PMA/ionomycin-stimulated human Jurkat T cells incubated for 30 mins prior to PMA/ionomycin stimulation measured after 5 hrs by luciferase reporter gene assay
|
[PMID: 23964991] |
| Jurkat | IC50 |
11 nM
Compound: 1; CyA
|
Immunosuppressive activity in human PMA/ionomycin stimulated Jurkat T cells assessed as suppression of IL2 production pretreated with cells followed by PMA/ionomycin stimulation measured after 13 hrs by ELISA
Immunosuppressive activity in human PMA/ionomycin stimulated Jurkat T cells assessed as suppression of IL2 production pretreated with cells followed by PMA/ionomycin stimulation measured after 13 hrs by ELISA
|
[PMID: 27647370] |
| Jurkat | IC50 |
1.9 μM
Compound: CsA
|
Immunosuppressive activity in human Jurkat cells assessed as reduction in PHA + PMA-induced IL-2 production after 48 hrs by ELISA
Immunosuppressive activity in human Jurkat cells assessed as reduction in PHA + PMA-induced IL-2 production after 48 hrs by ELISA
|
[PMID: 30579802] |
| Jurkat | IC50 |
12 nM
Compound: CsA
|
The compound was tested in vitro for inhibition of IL-2 release stimulated with PMA/ionomycin by Jurkat cells.
The compound was tested in vitro for inhibition of IL-2 release stimulated with PMA/ionomycin by Jurkat cells.
|
[PMID: 7473543] |
| Jurkat | IC50 |
>10 μM
Compound: CsA
|
In vitro inhibitory activity against Jurkat cell proliferation
In vitro inhibitory activity against Jurkat cell proliferation
|
[PMID: 9719606] |
| Jurkat | IC50 |
0.008 μM
Compound: Cyclosporin A
|
Effect on the transcription and release of IL-2 in a reporter-gene assay (RGA)
Effect on the transcription and release of IL-2 in a reporter-gene assay (RGA)
|
10.1016/S0960-894X(97)10005-1 |
| K562/R7 | IC50 |
0.7 μM
Compound: cyclosporin A
|
Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay
Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay
|
[PMID: 25634041] |
| KB | IC50 |
0.6 μM
Compound: CSA (cyclosporin A)
|
Inhibitory activity against KB cell line after 72 h of drug exposure
Inhibitory activity against KB cell line after 72 h of drug exposure
|
[PMID: 15481991] |
| KB 3-1 | EC50 |
1.2 μM
Compound: CSA (cyclosporin A)
|
Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h
Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h
|
[PMID: 15481991] |
| KB 3-1 | IC50 |
1.5 μM
Compound: CSA (cyclosporin A)
|
Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure
Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure
|
[PMID: 15481991] |
| KB 3-1 | IC50 |
23.9 μM
Compound: Cyclosporine A
|
Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
Cytotoxicity against human KB 3-1 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
|
[PMID: 35751979] |
| KB-V1 | IC50 |
7.95 μM
Compound: Cyclosporine A
|
Cytotoxicity against human KB-V1 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
Cytotoxicity against human KB-V1 cells assessed as cell growth inhibition incubated for 72 hrs by MTS assay
|
[PMID: 35751979] |
| L929 | IC50 |
33.9 μM
Compound: 2
|
Cytotoxicity against mouse L929 cells after 72 hrs
Cytotoxicity against mouse L929 cells after 72 hrs
|
[PMID: 22320402] |
| L929 | IC50 |
33.9 μM
Compound: cyclosporine A
|
Cytotoxicity against mouse L929 cells assessed as growth inhibition after 3 days by MTS assay
Cytotoxicity against mouse L929 cells assessed as growth inhibition after 3 days by MTS assay
|
[PMID: 24171478] |
| L929 | IC50 |
30 μM
Compound: cyclosporin A
|
Cytotoxicity against mouse L929 cells after 3 days by MTS assay
Cytotoxicity against mouse L929 cells after 3 days by MTS assay
|
[PMID: 25985195] |
| L929 | IC50 |
29.9 μM
Compound: Cyclosporin A
|
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay
|
[PMID: 34597896] |
| LLC-PK1 | IC50 |
0.7 μM
Compound: Cyclosporin a
|
Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
0.7 μM
Compound: Cyclosporin a
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
0.8 μM
Compound: Cyclosporin a
|
Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
0.8 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
4.8 μM
Compound: Cyclosporin a
|
Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
4.8 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells
|
[PMID: 12699389] |
| LLC-PK1 | IC50 |
3.66 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Digoxin: 0.8 uM) in MDR1-expressing LLC-PK1 cells
TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Digoxin: 0.8 uM) in MDR1-expressing LLC-PK1 cells
|
[PMID: 9914792] |
| Lymphocyte | IC50 |
0.054 μM
Compound: CsA
|
Immunosuppressive activity in lymphocytes by mixed lymphocyte reaction assay
Immunosuppressive activity in lymphocytes by mixed lymphocyte reaction assay
|
[PMID: 20064721] |
| Lymphocyte | IC50 |
0.054 μM
Compound: CsA
|
Immunosuppressive activity in peripheral blood lymphocytes isolated from two individuals assessed as proliferation using [methyl-3H]thymidine by mixed lymphocyte reaction assay
Immunosuppressive activity in peripheral blood lymphocytes isolated from two individuals assessed as proliferation using [methyl-3H]thymidine by mixed lymphocyte reaction assay
|
[PMID: 21171614] |
| Lymphocyte | EC50 |
60 nM
Compound: 1, CSA
|
Immunosuppressive activity in lymphocytes (unknown origin) by mixed lymphocyte reaction assay
Immunosuppressive activity in lymphocytes (unknown origin) by mixed lymphocyte reaction assay
|
[PMID: 24831536] |
| Lymphocyte | IC50 |
89 nM
Compound: CsA
|
Immunosuppressive activity in lymphocytes by MLR assay
Immunosuppressive activity in lymphocytes by MLR assay
|
[PMID: 24900866] |
| Lymphocyte | CC50 |
43.2 μM
Compound: CsA
|
Cytotoxicity against lymphocytes (unknown origin) assessed as decrease in cell viability
Cytotoxicity against lymphocytes (unknown origin) assessed as decrease in cell viability
|
[PMID: 29292227] |
| Lymphocyte | IC50 |
0.2 μg/mL
Compound: Cyclosporin A
|
Immunosuppressive activity in human lymphocytes by mixed lymphocyte reaction assay
Immunosuppressive activity in human lymphocytes by mixed lymphocyte reaction assay
|
[PMID: 3373220] |
| MDCK | IC50 |
>14.8 μM
Compound: Cs
|
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral replication
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| MDCK | IC50 |
>14.8 μM
Compound: Cs
|
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral replication
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| MDCK | IC50 |
>14.8 μM
Compound: Cs
|
Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of viral replication
Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| MDCK | IC50 |
>9.9 μM
Compound: Cs
|
Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of viral replication
Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| MDCK-II | IC50 |
9.34 μM
Compound: CsA
|
Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells
Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells
|
[PMID: 17664327] |
| MDCK-II | IC50 |
13.6 μM
Compound: cyclosporin A
|
Inhibition of human MRP2 expressed in dog MDCK2 cells
Inhibition of human MRP2 expressed in dog MDCK2 cells
|
[PMID: 18707884] |
| MDCK-II | IC50 |
25.6 μM
Compound: Cyclosporine A
|
Inhibition of ABCC2 (unknown origin) expressed in MDCK2 cells assessed as inhibition of calcein-AM efflux measured after 30 mins in presence of ABCB1 inhibitor GF120918 and ABCC1 inhibitor MK-571 by flow cytometry
Inhibition of ABCC2 (unknown origin) expressed in MDCK2 cells assessed as inhibition of calcein-AM efflux measured after 30 mins in presence of ABCB1 inhibitor GF120918 and ABCC1 inhibitor MK-571 by flow cytometry
|
[PMID: 27393949] |
| MT4 | IC50 |
>0.83 μM
Compound: Cs
|
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay
Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay
|
[PMID: 18212100] |
| MT4 | EC50 |
450 nM
Compound: 1, CsA
|
Antiviral activity against HIV1 3B infected in human MT4 cells coinfected with HTLV1 assessed as reduction in virus-induced cytopathogenicity after 4 days by MTT assay
Antiviral activity against HIV1 3B infected in human MT4 cells coinfected with HTLV1 assessed as reduction in virus-induced cytopathogenicity after 4 days by MTT assay
|
[PMID: 23849880] |
| MT4 | CC50 |
5608 nM
Compound: CSA
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by cell-titer glo assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by cell-titer glo assay
|
[PMID: 30074795] |
| NCI/ADR-RES | IC50 |
0.518 μM
Compound: Cyclosporin A
|
Cytotoxicity against DOX-resistant human MCF7/ADR cells assessed as doxorubicin IC50 incubated for 48 hrs in presence of doxorubicin by CCK8 assay
Cytotoxicity against DOX-resistant human MCF7/ADR cells assessed as doxorubicin IC50 incubated for 48 hrs in presence of doxorubicin by CCK8 assay
|
[PMID: 36645980] |
| NCI/ADR-RES | IC50 |
0.86 μM
Compound: CyclosporinA
|
Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay
Cytotoxicity against human MCF7ADR cells assessed as doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK8 assay
|
[PMID: 37229830] |
| NCI/ADR-RES | IC50 |
0.29 μM
Compound: Cyclosporin
|
Reversal of P-gp mediated multidrug resistance in doxorubicin-resistant human MCF-7/ADR cells assessed as doxorubicin IC50 incubated for 48 hrs by CCK-8 assay (Rvb = 12.66 +/- 1.45 microM)
Reversal of P-gp mediated multidrug resistance in doxorubicin-resistant human MCF-7/ADR cells assessed as doxorubicin IC50 incubated for 48 hrs by CCK-8 assay (Rvb = 12.66 +/- 1.45 microM)
|
[PMID: 38364715] |
| Neutrophil | IC50 |
0.047 nM
Compound: CSA
|
Reduction of chemotaxis in human neutrophils assessed as inhibition of fMLP-OMe-induced cell migration pretreated 10 mins before fMLP-OMe challenge
Reduction of chemotaxis in human neutrophils assessed as inhibition of fMLP-OMe-induced cell migration pretreated 10 mins before fMLP-OMe challenge
|
[PMID: 19362486] |
| NIH-3T3-G185 | IC50 |
1.4 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
1.7 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
1.7 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
1.8 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
2.1 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
2.4 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| NIH-3T3-G185 | IC50 |
4.3 μM
Compound: Cyclosporin A
|
TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells
TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells
|
[PMID: 11716514] |
| PBMC | IC50 |
12 nM
Compound: cyclosporin A
|
Antiproliferative activity against human PBMC
Antiproliferative activity against human PBMC
|
[PMID: 15679309] |
| PBMC | IC50 |
0.056 μM
Compound: Cs
|
Antiproliferative activity against mouse PBMC with MLR assessed as inhibition of [3H]thymidine incorporation after 18 hrs
Antiproliferative activity against mouse PBMC with MLR assessed as inhibition of [3H]thymidine incorporation after 18 hrs
|
[PMID: 18212100] |
| PBMC | EC50 |
0.0031 μM
Compound: CsA
|
Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay
Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay
|
[PMID: 19933795] |
| PBMC | IC50 |
3 nM
Compound: CsA
|
Immunosuppressive activity in human PBMC isolated from two individuals assessed as inhibition of proliferation using [3H]thymidine by mixed lymphocyte reaction assay
Immunosuppressive activity in human PBMC isolated from two individuals assessed as inhibition of proliferation using [3H]thymidine by mixed lymphocyte reaction assay
|
10.1039/C1MD00227A |
| RD | CC50 |
>10 μM
Compound: CsA
|
Cytotoxicity against human RD cells after 24 hrs by WST-1 assay
Cytotoxicity against human RD cells after 24 hrs by WST-1 assay
|
[PMID: 26564266] |
| RD | EC50 |
3.66 μM
Compound: CsA
|
Antiviral activity against EV71 infected in RD cells after 24 hrs by luciferase assay
Antiviral activity against EV71 infected in RD cells after 24 hrs by luciferase assay
|
[PMID: 26564266] |
| Sf21 | IC50 |
0.5 μM
Compound: Cyclosporine
|
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Sf21 | IC50 |
0.6 μM
Compound: Cyclosporine
|
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake
|
[PMID: 21965623] |
| Splenocyte | CC50 |
0.88 μM
Compound: CsA
|
Cytotoxicity against splenocytes after 48 hrs by MTT assay
Cytotoxicity against splenocytes after 48 hrs by MTT assay
|
[PMID: 19481938] |
| Splenocyte | IC50 |
0.01 μM
Compound: CsA
|
Immunosuppressive activity in splenocytes assessed as inhibition of concanavalin A-induced proliferation after 48 hrs by [3H]thymidine incorporation assay
Immunosuppressive activity in splenocytes assessed as inhibition of concanavalin A-induced proliferation after 48 hrs by [3H]thymidine incorporation assay
|
[PMID: 19481938] |
| Splenocyte | IC50 |
0.07 μM
Compound: CsA
|
Immunosuppressive activity in splenocytes assessed as inhibition of LPS-induced proliferation after 48 hrs by [3H]thymidine incorporation assay
Immunosuppressive activity in splenocytes assessed as inhibition of LPS-induced proliferation after 48 hrs by [3H]thymidine incorporation assay
|
[PMID: 19481938] |
| Splenocyte | IC50 |
0.01 μM
Compound: CsA
|
Immunosuppressive activity in mouse splenocytes assessed as inhibition of allogenic mixed lymphocyte reaction
Immunosuppressive activity in mouse splenocytes assessed as inhibition of allogenic mixed lymphocyte reaction
|
[PMID: 19502058] |
| Splenocyte | IC50 |
10 nM
Compound: Cyclosporine A
|
Immunosuppressive activity in human splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay
Immunosuppressive activity in human splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay
|
[PMID: 19827831] |
| Splenocyte | IC50 |
17 nM
Compound: Cyclosporine A
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay
|
[PMID: 19827831] |
| Splenocyte | IC50 |
30 nM
Compound: 1, CsA
|
Immunosuppressant activity in mouse splenocytes by mixed-leukocyte reaction assay
Immunosuppressant activity in mouse splenocytes by mixed-leukocyte reaction assay
|
[PMID: 23017885] |
| Splenocyte | IC50 |
0.01 μg/mL
Compound: Cyclosporine A
|
Antiproliferative activity against concanavalin A-stimulated BALB/c mouse splenocytes after 72 hrs by AlamarBlue assay
Antiproliferative activity against concanavalin A-stimulated BALB/c mouse splenocytes after 72 hrs by AlamarBlue assay
|
[PMID: 23167554] |
| Splenocyte | IC50 |
0.1 μM
Compound: Cyclosporin A
|
Immunosupressive activity in OVA323-339 peptide-stimulated OT-2 T cell receptor transgenic mouse splenocytes assessed as inhibition of T cell proliferation after 3 days by MTT assay
Immunosupressive activity in OVA323-339 peptide-stimulated OT-2 T cell receptor transgenic mouse splenocytes assessed as inhibition of T cell proliferation after 3 days by MTT assay
|
[PMID: 25537268] |
| Splenocyte | CC50 |
1.2 μM
Compound: CsA
|
Cytotoxicity against BALB/c mouse splenocytes after 48 hrs by CCK-8 assay
Cytotoxicity against BALB/c mouse splenocytes after 48 hrs by CCK-8 assay
|
[PMID: 30500185] |
| Splenocyte | IC50 |
0.04 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A stimulated T-cell proliferation by measuring [3H]-thymidine uptake preincubated for 48 hrs followed by concanavalin A stimulation and [3H]-thymidine addition f
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A stimulated T-cell proliferation by measuring [3H]-thymidine uptake preincubated for 48 hrs followed by concanavalin A stimulation and [3H]-thymidine addition f
|
[PMID: 30500185] |
| Splenocyte | IC50 |
0.4 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation by measuring [3H]-thymidine uptake preincubated for 48 hrs followed by LPS stimulation and [3H]-thymidine addition for 8 hrs measured afte
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation by measuring [3H]-thymidine uptake preincubated for 48 hrs followed by LPS stimulation and [3H]-thymidine addition for 8 hrs measured afte
|
[PMID: 30500185] |
| Splenocyte | CC50 |
1.2 μM
Compound: CsA
|
Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay
|
[PMID: 31253536] |
| Splenocyte | IC50 |
0.04 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation by measuring [3H]-thymidine uptake preincubated before concanavalin A stimulation for 48 hrs followed by [3H]-thymidine additio
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation by measuring [3H]-thymidine uptake preincubated before concanavalin A stimulation for 48 hrs followed by [3H]-thymidine additio
|
[PMID: 31253536] |
| Splenocyte | IC50 |
0.4 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation by measuring [3H]-thymidine uptake preincubated before LPS stimulation for 48 hrs followed by [3H]-thymidine addition for 8 hrs by beta-sc
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation by measuring [3H]-thymidine uptake preincubated before LPS stimulation for 48 hrs followed by [3H]-thymidine addition for 8 hrs by beta-sc
|
[PMID: 31253536] |
| Splenocyte | IC50 |
0.3 μM
Compound: Cyclosporine A
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation incubated for 48 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation incubated for 48 hrs by MTT assay
|
[PMID: 33544615] |
| Splenocyte | IC50 |
10.15 μM
Compound: CsA
|
Cytotoxicity against BALB/c mouse splenocyte assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay
Cytotoxicity against BALB/c mouse splenocyte assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay
|
[PMID: 33973788] |
| Splenocyte | CC50 |
>2.5 μM
Compound: CsA
|
Cytotoxicity in BALB/c mouse Splenocyte assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Cytotoxicity in BALB/c mouse Splenocyte assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 35104138] |
| Splenocyte | IC50 |
0.03 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of concanavalin A induced T-cell proliferation by [3H]-thymidine incorporation based beta scintillation counter analysis
Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of concanavalin A induced T-cell proliferation by [3H]-thymidine incorporation based beta scintillation counter analysis
|
[PMID: 35104138] |
| Splenocyte | IC50 |
0.32 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of LPS induced B-cell proliferation by [3H]-thymidine incorporation based beta scintillation counter analysis
Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of LPS induced B-cell proliferation by [3H]-thymidine incorporation based beta scintillation counter analysis
|
[PMID: 35104138] |
| Splenocyte | CC50 |
7.33 μM
Compound: CsA
|
Cytotoxicity in BALB/c mouse Splenocyte assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in BALB/c mouse Splenocyte assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 35678710] |
| Splenocyte | EC50 |
0.03 μM
Compound: Cyclosporine A
|
Immunosuppressive activity in BALB/c mouse splenocyte assessed as reduction in ConA-induced mouse T-lymphocytes proliferation incubated for 48 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse splenocyte assessed as reduction in ConA-induced mouse T-lymphocytes proliferation incubated for 48 hrs by MTT assay
|
[PMID: 36596229] |
| Splenocyte | CC50 |
5.5 μM
Compound: CsA
|
Cytotoxicity against BALB/c mouse splenocytes incubated for 48 hrs by MTT assay
Cytotoxicity against BALB/c mouse splenocytes incubated for 48 hrs by MTT assay
|
[PMID: 37307145] |
| Splenocyte | IC50 |
0.02 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of ConA-induced T cell proliferation by measuring [3H]-thymidine uptake by beta scintillation counter analysis
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of ConA-induced T cell proliferation by measuring [3H]-thymidine uptake by beta scintillation counter analysis
|
[PMID: 37307145] |
| Splenocyte | IC50 |
0.55 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-induced B cell proliferation by measuring [3H]-thymidine uptake by beta scintillation counter analysis
Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-induced B cell proliferation by measuring [3H]-thymidine uptake by beta scintillation counter analysis
|
[PMID: 37307145] |
| Splenocyte | IC50 |
0.17 μM
Compound: Cyclosporine A
|
Immunosuppressive activity in mouse splenocyte assessed as reduction in ConA-induced mouse T-cell proliferation
Immunosuppressive activity in mouse splenocyte assessed as reduction in ConA-induced mouse T-cell proliferation
|
[PMID: 38128907] |
| Splenocyte | IC50 |
0.07 μg/mL
Compound: Cyclosporine A
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse T-lymphocytes proliferation
Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse T-lymphocytes proliferation
|
[PMID: 38441877] |
| T cell line | CC50 |
9.8 μM
Compound: CsA
|
Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay
Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay
|
[PMID: 32822186] |
| T cell line | IC50 |
26 nM
Compound: CsA
|
Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay
Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay
|
[PMID: 32822186] |
| T-cell | IC50 |
0.04 μg/mL
Compound: cyclosporin A
|
Immunosuppressant activity in mouse T cells assessed as inhibition of concanavalin A-induced cell proliferation
Immunosuppressant activity in mouse T cells assessed as inhibition of concanavalin A-induced cell proliferation
|
[PMID: 11575965] |
| T-cell | IC50 |
0.34 μM
Compound: cyclosporin A
|
Inhibition of PHA-induced human T cell proliferation after 24 hrs by MTT assay
Inhibition of PHA-induced human T cell proliferation after 24 hrs by MTT assay
|
[PMID: 11678649] |
| T-cell | IC50 |
32 nM
Compound: CSA
|
Inhibition of allogenic cells-stimulated proliferation in mouse T cells by mixed lymphocyte reaction method
Inhibition of allogenic cells-stimulated proliferation in mouse T cells by mixed lymphocyte reaction method
|
[PMID: 14593182] |
| T-cell | IC50 |
74 nM
Compound: CSA
|
Inhibition of allogenic cells-stimulated proliferation in human T cells by mixed lymphocyte reaction method
Inhibition of allogenic cells-stimulated proliferation in human T cells by mixed lymphocyte reaction method
|
[PMID: 14593182] |
| T-cell | IC50 |
>10000 nM
Compound: CSA
|
Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting
Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting
|
[PMID: 14593182] |
| T-cell | IC50 |
0.04 μg/mL
Compound: cyclosporin A
|
Immunosuppressive activity in BALB/c mouse splenic T lymphocytes assessed as inhibition of Con A-induced cell proliferation after 72 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse splenic T lymphocytes assessed as inhibition of Con A-induced cell proliferation after 72 hrs by MTT assay
|
[PMID: 14738397] |
| T-cell | ED50 |
50 nM
Compound: Cyclosporin A
|
Inhibition of T-cell proliferation
Inhibition of T-cell proliferation
|
[PMID: 15357990] |
| T-cell | IC50 |
0.00137 μM
Compound: CsA
|
Inhibition of ConA-induced BALB/c mouse T cell proliferation
Inhibition of ConA-induced BALB/c mouse T cell proliferation
|
[PMID: 17081761] |
| T-cell | IC50 |
550 nM
Compound: CsA
|
Immunosuppressive activity in concanavalin A-activated T cell assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting
Immunosuppressive activity in concanavalin A-activated T cell assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting
|
[PMID: 19502058] |
| T-cell | CC50 |
15.82 μM
Compound: CsA
|
Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay
Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay
|
[PMID: 21131104] |
| T-cell | IC50 |
0.06 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay
|
[PMID: 21131104] |
| T-cell | IC50 |
14 nM
Compound: cyclosporin A
|
Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay
Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay
|
[PMID: 21456524] |
| T-cell | IC50 |
8.97 μM
Compound: CYA
|
Inhibition of CD4 expression in human CD4+ T cells
Inhibition of CD4 expression in human CD4+ T cells
|
[PMID: 22101135] |
| T-cell | CC50 |
13.78 μM
Compound: CsA
|
Cytotoxicity against lymph node T cell after 24 hrs by MTT assay
Cytotoxicity against lymph node T cell after 24 hrs by MTT assay
|
[PMID: 22300886] |
| T-cell | IC50 |
0.07 μM
Compound: CsA
|
Immunosuppressive activity in lymph node T cell assessed as inhibition of ConA-stimulated cell proliferation after 72 hrs by MTT assay
Immunosuppressive activity in lymph node T cell assessed as inhibition of ConA-stimulated cell proliferation after 72 hrs by MTT assay
|
[PMID: 22300886] |
| T-cell | IC50 |
2.12 μM
Compound: csa
|
Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of ConA-induced T cell proliferation incubated 24 hrs post ConA-induction for 72 hrs by MTT assay
Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of ConA-induced T cell proliferation incubated 24 hrs post ConA-induction for 72 hrs by MTT assay
|
[PMID: 22727369] |
| T-cell | IC50 |
0.011 μM
Compound: CsA
|
Immunosuppressive activity in mouse T cells assessed as inhibition of two way mixed lymphocyte reaction after 4 days by MTT assay
Immunosuppressive activity in mouse T cells assessed as inhibition of two way mixed lymphocyte reaction after 4 days by MTT assay
|
[PMID: 22984987] |
| T-cell | IC50 |
0.57 μM
Compound: CsA
|
Inhibition of PI3K-gamma in mouse lymph node cells assessed as inhibition of ConA-stimulated T cell proliferation
Inhibition of PI3K-gamma in mouse lymph node cells assessed as inhibition of ConA-stimulated T cell proliferation
|
[PMID: 26720154] |
| T-cell | EC50 |
6.4 nM
Compound: CsA
|
Immunosuppressive activity in human PBMC assessed as inhibition of anti-human CD3-induced T-cell proliferation after 4 days by CellTrace violet cell proliferation dye based FACS analysis
Immunosuppressive activity in human PBMC assessed as inhibition of anti-human CD3-induced T-cell proliferation after 4 days by CellTrace violet cell proliferation dye based FACS analysis
|
[PMID: 28075591] |
| T-cell | CC50 |
4.5 μM
Compound: Cyclosporin A
|
Cytotoxic activity against BALB/c mouse T-lymphocytes assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxic activity against BALB/c mouse T-lymphocytes assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 28294615] |
| T-cell | IC50 |
0.08 μM
Compound: Cyclosporin A
|
Inhibition of ConA-induced cell proliferation of BALB/c mouse T-lymphocytes assessed as reduction in [3H]thymidine incorporation incubated for 48 hrs by beta scintillation counting method
Inhibition of ConA-induced cell proliferation of BALB/c mouse T-lymphocytes assessed as reduction in [3H]thymidine incorporation incubated for 48 hrs by beta scintillation counting method
|
[PMID: 28294615] |
| T-cell | IC50 |
0.26 μM
Compound: CsA
|
Inhibition of ConA-induced T lymphocytes (unknown origin) proliferation
Inhibition of ConA-induced T lymphocytes (unknown origin) proliferation
|
[PMID: 29292227] |
| T-cell | IC50 |
0.2 μM
Compound: CsA
|
Immunosuppressant activity in human T lymphocytes assessed as inhibition of anti-human CD3 and anti-human CD28 monoclonal antibody-induced T lymphocyte proliferation incubated for 72 hrs by FACS analysis
Immunosuppressant activity in human T lymphocytes assessed as inhibition of anti-human CD3 and anti-human CD28 monoclonal antibody-induced T lymphocyte proliferation incubated for 72 hrs by FACS analysis
|
[PMID: 31181920] |
| T-cell | IC50 |
0.1 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse T cells assessed as reduction in ConA-induced cell proliferation
Immunosuppressive activity in BALB/c mouse T cells assessed as reduction in ConA-induced cell proliferation
|
[PMID: 32323537] |
| T-cell | IC50 |
0.046 μg/mL
Compound: Cyclosporin A
|
Immunosuppressive activity in guinea pig T cell assessed as inhibition of mitogenesis
Immunosuppressive activity in guinea pig T cell assessed as inhibition of mitogenesis
|
[PMID: 3373220] |
| T-cell | IC50 |
0.28 μg/mL
Compound: Cyclosporin A
|
Immunosuppressive activity in human T cell assessed as inhibition of mitogenesis
Immunosuppressive activity in human T cell assessed as inhibition of mitogenesis
|
[PMID: 3373220] |
| T-cell | IC50 |
0.03 μM
Compound: CsA
|
Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse T-lymphocytes proliferation incubated for 8 hrs by beta scintillation counting based [3H]thymidine incorporation assay
Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse T-lymphocytes proliferation incubated for 8 hrs by beta scintillation counting based [3H]thymidine incorporation assay
|
[PMID: 35678710] |
| T-cell | IC50 |
1.05 μM
Compound: Cyclosporine A
|
Immunomodulatory activity in C57BL/6 mouse mesenteric lymph node T cells assessed as inhibition of concanavalin A stimulated T-cell proliferation incubated for 68 hrs by CCK-8 assay
Immunomodulatory activity in C57BL/6 mouse mesenteric lymph node T cells assessed as inhibition of concanavalin A stimulated T-cell proliferation incubated for 68 hrs by CCK-8 assay
|
[PMID: 37017305] |
| T-cell | IC50 |
13.7 nM
Compound: CsA
|
In vitro inhibitory activity against human T-cell proliferation.
In vitro inhibitory activity against human T-cell proliferation.
|
[PMID: 7537331] |
| T-cell | IC50 |
8.1 nM
Compound: CsA
|
In vitro inhibitory activity against human T-cell production of lymphokine IL-2
In vitro inhibitory activity against human T-cell production of lymphokine IL-2
|
[PMID: 7537331] |
| T-cell | IC50 |
0.007 μM
Compound: Cyclosporin A
|
Compound was tested for inhibition of IL-2 secretion in mouse T cell line
Compound was tested for inhibition of IL-2 secretion in mouse T cell line
|
10.1016/S0960-894X(97)10005-1 |
| Ventricular myocyte | IC50 |
2 μM
Compound: Cyclosporin A
|
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes
|
[PMID: 22761000] |
| Vero | IC50 |
>16.6 μM
Compound: Cs
|
Antiviral activity against Yellow fever virus 17D infected in african green monkey Vero cells assessed as inhibition of viral replication
Antiviral activity against Yellow fever virus 17D infected in african green monkey Vero cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| Vero | IC50 |
>25 μM
Compound: Cs
|
Antiviral activity against Coxsackie B3 infected in african green monkey Vero cells assessed as inhibition of viral replication
Antiviral activity against Coxsackie B3 infected in african green monkey Vero cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| Vero | IC50 |
>8.3 μM
Compound: Cs
|
Antiviral activity against SARS coronavirus infected in african green monkey Vero cells assessed as inhibition of viral replication
Antiviral activity against SARS coronavirus infected in african green monkey Vero cells assessed as inhibition of viral replication
|
[PMID: 18212100] |
| Vero | IC50 |
8 μM
Compound: Cs
|
Antiviral activity against West Nile virus infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay
Antiviral activity against West Nile virus infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay
|
[PMID: 19451286] |
| Vero | IC50 |
≤0.5 μM
Compound: Cs
|
Antiviral activity against Dengue virus 1 infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay
Antiviral activity against Dengue virus 1 infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay
|
[PMID: 19451286] |
| Vero | CC50 |
>50 μM
Compound: Cyclosporine
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
5.82 μM
Compound: Cyclosporine
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
Cyclosporin A is able to bind with the cyclophilin in T cells[1].
Cyclosporin A works by forming a Cyclophilin-Cyclosporin A complex to inhibit calcineurin[2].
Cyclosporin A inhibits calcineurin in stimulated cells with an IC50 value of 7 nM[3].
Cyclosporin A suppresses the nuclear translocation of NF-AT[4].
Cyclosporin A shows an effect on mitochondria via preventing the MTP from opening with an IC50 of 39 nM[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Cyclosporin A can be used to construct uremia models. In male Wistar rats (weighing 140-200 g, aged 5-6 weeks), the pharmacokinetic parameters following intravenous administration of Cyclosporin A (10 mg/kg) show an area under the curve of 27.3 μg·h/mL, a half-life of 6.9 hours, and a volume of distribution of 3.7 L/kg[9].
Administration: 30 mg/kg • SC • daily for 16 weeks
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 59865-13-3
-
Appearance Solid
-
Masse moléculaire 1202.61
-
Formule C62H111N11O12
-
Color White to off-white
-
SMILES
C/C=C/C[C@H]([C@@H](O)[C@@]1(N(C)C([C@]([H])(C(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@]([H])(CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@@H](N(C([C@@]([H])(NC([C@@H](N(C(CN(C([C@@H](NC1=O)CC)=O)C)=O)C)CC(C)C)=O)C(C)C)=O)C)CC(C)C)=O)=O)=O)=O)=O)=O)[H])C
-
Synonyms
Cyclosporine A; Ciclosporin A; CsA
-
Structure Classification
-
Initial Source
the fungus Beauveria nivea.
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (213)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting NFATc1-regulated MTHFD2 one-carbon metabolism to suppress sustained T-cell-mediated inflammation in rheumatoid arthritis. [Abstract]2026 Jun 10;11(1):226. PMID: 42270592 -
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Science
2026 Jul 2;393(6806):eaef0825. PMID: 42391361 -
Cell Metab
Hepatocyte-to-intestinal stem cell remote communication regulates blood glucose homeostasis. [Abstract]2026 Jul 7;38(7):1367-1384.e9. PMID: 42309059 -
Cell Res
Transient mechanical activation of the Piezo1 channel facilitates ex vivo expansion of hematopoietic stem cells. [Abstract]2026 Jan 9. PMID: 41507440 -
Nat Metab
2023 Mar;5(3):481-494. PMID: 36879120 -
Bioact Mater
Synergistic restoration of spinal cord injury through hyaluronic acid conjugated hydrogel-polydopamine nanoparticles combined with human mesenchymal stem cell transplantation. [Abstract]2025 Feb 12:46:569-581. PMID: 40027446 -
Bioact Mater
cGAMP-targeting injectable hydrogel system promotes periodontal restoration by alleviating cGAS-STING pathway activation. [Abstract]2025 Feb 13:48:55-70. PMID: 40303968 -
Bioact Mater
Engineered human spinal cord-like tissues with dorsal and ventral neuronal progenitors for spinal cord injury repair in rats and monkeys. [Abstract]2023 Mar 29:27:125-137. PMID: 37064803 -
Bioact Mater
Transplantation of neural stem progenitor cells from different sources for severe spinal cord injury repair in rat. [Abstract]2022 Nov 23:23:300-313. PMID: 36439085 -
Cell Stem Cell
Paired pre- and post-transplant human immunoprofiling identifies an IFN-γ-JAK1 axis limiting stem-cell-derived RPE engraftment. [Abstract]2026 Jul 2;33(7):1127-1143.e10. PMID: 42309064 -
Autophagy
Mechanical stress-mediated ferritinophagy aggravates cartilage endplate degeneration via a PIEZO1-NCOA4-ZBP1 axis. [Abstract]2026 May 31:1-22. PMID: 42153663 -
Autophagy
Impaired mitophagy contributes to osteogenesis and mineralization disorders in fibrous dysplasia. [Abstract]2026 Mar 15:1-22. PMID: 41803635 -
Protein Cell
2025 Dec 8:pwaf109. PMID: 41359778 -
Nat Commun
Helicobacter hepaticus promotes hepatic steatosis through CdtB-induced mitochondrial stress and lipid metabolism reprogramming. [Abstract]2025 Aug 26;16(1):7954. PMID: 40858606 -
Nat Commun
Endothelial major vault protein alleviates vascular remodeling via promoting Parkin-mediated mitophagy. [Abstract]2025 May 10;16(1):4365. PMID: 40348769 -
Nat Commun
2024 Aug 6;15(1):6685. PMID: 39107301 -
Nat Commun
Perfluoroalkyl substance pollutants activate the innate immune system through the AIM2 inflammasome. [Abstract]2021 May 18;12(1):2915. PMID: 34006824
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 May 18;12(1):2915. [Abstract]
Immunoblot analysis of Cytochrome c from cytosolic extracts and mitochondria from indicated cells pre-treated with DMSO or Cyclosporine A (50 μM) for 1 h, followed with PFOS treatment (150 μM, 6 h).
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 May 18;12(1):2915. [Abstract]
THP-1-derived macrophages were treated with DMSO or cyclosporine A (50 μM) for 1 h followed by PFOS (150 μM, 6 h), poly (dA:dT) (2 μg/ml, 6 h) treatment or pre-treated with LPS (200 ng/ml, 3 h) followed ATP (5 mM, 6 h) treatment.
-
Exp Mol Med
Cytosolic escape of mitochondrial DNA triggers cGAS-STING-NLRP3 axis-dependent nucleus pulposus cell pyroptosis. [Abstract]2022 Feb;54(2):129-142. PMID: 35145201
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2022 Feb;54(2):129-142. [Abstract]
Representative western blotting images of cGAS and STING in the Cyclosporine (CsA; 10 μM; for 24 h)- or DMSO-treated NP cells.
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2022 Feb;54(2):129-142. [Abstract]
Representative immunofluorescence images of STING with different degrees of polymerization in the Cyclosporine (CsA; 10 μM; for 24 h)- or DMSO-treated NP cells.
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2022 Feb;54(2):129-142. [Abstract]
Representative western blotting images of NLRP3, ASC, pro-CASP-1, cleaved CASP-1, GSDMD, and cleaved GSDMD in the (CsA; 10 μM; for 24 h)- or DMSO-treated NP cells.
-
ACS Nano
Programmed Cell Death Protein 1 Engagement Impairs Cytoskeletal Forces and Nuclear Mechanotransduction in T Cells. [Abstract]2025 Nov 25;19(46):39667-39681. PMID: 41221724 -
J Adv Res
Conjugated bile acids facilitate cholangiocyte senescence to promote cholestatic liver diseases via STING signaling. [Abstract]2026 Mar 12:S2090-1232(26)00239-0. PMID: 41831676 -
Redox Biol
Histidine metabolic reprogramming drives oxidative stress induced mtDNA release to promote necroptosis and airway inflammation in severe asthma. [Abstract]2026 Jun 27:95:104280. PMID: 42372708 -
Redox Biol
Extracellular vesicle-mediated delivery of mitochondrial circRNA MTCO2 protects against cerebral ischemia by modulating mPTP-dependent ferroptosis. [Abstract]2025 Aug 5:86:103806. PMID: 40768899 -
Redox Biol
CypD induced ROS output promotes intracranial aneurysm formation and rupture by 8-OHdG/NLRP3/MMP9 pathway. [Abstract]2023 Nov:67:102887. PMID: 37717465 -
Redox Biol
Cationic antimicrobial peptide NRC-03 induces oral squamous cell carcinoma cell apoptosis via CypD-mPTP axis-mediated mitochondrial oxidative stress. [Abstract]2022 Aug;54:102355. PMID: 35660629
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Aug;54:102355. [Abstract]
Cells are treated with or without Cyclosporine A (CsA; 2 μM) for 4 h in presence of NRC-03 (45 μg/mL). Cell viability determined by CCK-8.
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Redox Biol. 2022 Aug;54:102355. [Abstract]
Cells are treated with or without Cyclosporine A (CsA; 2 μM) for 4 h in presence of NRC-03 (45 μg/mL). TUNEL immunofluorescence staining and quantification of TUNEL positive cells.
-
J Nanobiotechnology
Ag2Se quantum dots neurotoxicity: mitochondrial stress drives ferroptosis-dependent microglial inflammation. [Abstract]2026 Apr 2;24(1):431. PMID: 41928263 -
Theranostics
Reprogramming Exosomes to Escape from Immune Surveillance for Mitochondrial Protection in Hepatic Ischemia-Reperfusion Injury. [Abstract]2024 Jan 1;14(1):116-132. PMID: 38164154 -
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334 -
Adv Sci (Weinh)
NADH-Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis. [Abstract]2025 Dec 5:e20444. PMID: 41346305 -
Adv Sci (Weinh)
LPS-Induced Mitochondrial Damage via SLC41A1-Mediated Magnesium Ion Efflux Leads to the Pyroptosis of Dental Stem Cells. [Abstract]2025 Aug 19:e05666. PMID: 40831212 -
Adv Sci (Weinh)
Mesenchymal Stem Cell Membrane-Camouflaged Liposomes for Biomimetic Delivery of Cyclosporine A for Hepatic Ischemia-Reperfusion Injury Prevention. [Abstract]2024 Jun 20:e2404171. PMID: 39031840
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 20:e2404171. [Abstract]
Cell viability of H/R‐injured cells after being treated with free CsA, CLs, and MMCLs at CsA concentrations of 0 − 500 ng/mL as evaluated by CCK‐8 assay.
-
Adv Sci (Weinh)
Glutamine Metabolism Underlies the Functional Similarity of T Cells between Nile Tilapia and Tetrapod. [Abstract]2023 Apr;10(12):e2201164. PMID: 36890649
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Apr;10(12):e2201164. [Abstract]
Relative mRNA levels of indicated molecules in spleen leukocytes. N) Healthy tilapia were injected with 293T cells on day 1 and 3, and treated with 10 mg/kg Cyclosporine A (CyA) on day 1, 3, and 5. Spleen T cells were sorted on day 6 and incubated with 293T or NIH3T3 cells for 8 h, and LDH release was detected.
-
Adv Sci (Weinh)
MCU Upregulation Overactivates Mitophagy by Promoting VDAC1 Dimerization and Ubiquitination in the Hepatotoxicity of Cadmium. [Abstract]2023 Mar;10(7):e2203869. PMID: 36642847 -
Adv Sci (Weinh)
Mitochondrial Damage-Induced Innate Immune Activation in Vascular Smooth Muscle Cells Promotes Chronic Kidney Disease-Associated Plaque Vulnerability. [Abstract]2021 Jan 6;8(5):2002738. PMID: 33717842 -
Sci Adv
2023 Feb 10;9(6):eade8829. PMID: 36753555 -
Cell Death Differ
2026 Jun 24. PMID: 42337094 -
Research (Wash D C)
Extracellular Vesicle-Mediated Delivery of Mitochondrial Circular RNA MTCO2 Protects against Cerebral Ischemia by Modulating mPTP-Dependent Ferroptosis. [Abstract]2026 Apr 14:9:1232. PMID: 41988019 -
Research (Wash D C)
Mitochondrial 8-Oxoguanine DNA Glycosylase 1-Mitochondrial Permeability Transition Pore Axis Drives Mitochondrial DNA Escape and Accelerates Osteoarthritis Progression. [Abstract]2026 Apr 15:9:1235. PMID: 41993093 -
Pharmacol Res
SERCA2 dysfunction drives vascular calcification via coupling with TSPO-MCU at mitochondria-associated endoplasmic reticulum membranes. [Abstract]2026 May:227:108177. PMID: 41932666 -
Cell Death Dis
Generation of proliferative hESC-derived grape-clustered hepatocyte organoids with multipolar architecture as regenerative counterpart via synergy of YAP and IGF2 pathways. [Abstract]2026 Mar 26;17(1):381. PMID: 41888105 -
Cell Death Dis
Mitochondrial DNA drives NLRP3-IL-1β axis activation in microglia by binding to NLRP3, leading to neurodegeneration in Parkinson's disease models. [Abstract]2026 Feb 10;17(1):213. PMID: 41667433 -
Pharmacol Res
2023 Sep:195:106881. PMID: 37541638 -
Cell Death Dis
RANK promotes colorectal cancer migration and invasion by activating the Ca2+-calcineurin/NFATC1-ACP5 axis. [Abstract]2021 Apr 1;12(4):336. PMID: 33795653
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Apr 1;12(4):336. [Abstract]
Immunofluorescence staining of subcellular localization of NFATC1 in RANK overexpression and control cells with or without treatment of 10 μg/mL Cyclosporin A (CsA).
-
Cell Death Dis
Mitochondrial quality control protects photoreceptors against oxidative stress in the H2O2-induced models of retinal degeneration diseases. [Abstract]2021 Apr 20;12(5):413. PMID: 33879768
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2021 Apr 20;12(5):413. [Abstract]
Inhibition of NR-induced increase of co-localized puncta (LC3 and TOM20) after 1 μMCyclosporin A (CsA) pretreatment.
-
Cell Death Dis
Hirsutine induces mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3β pathway in human lung cancer cells. [Abstract]2018 May 22;9(6):598. PMID: 29789524
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):598. [Abstract]
A549 cells are pretreated with 5 µM Cyclosporin A (CSA) for 2 h, followed by treatment with 80 μM Hirsutine for 24 h. equal amount of lysates are subjected to immunoprecipitation using anti-ANT1 antibody, the associated CypD is determined using immunoblotting.
-
Environ Sci Technol
Determining the Cytotoxicity of Rare Earth Element Nanoparticles in Macrophages and the Involvement of Membrane Damage. [Abstract]2017 Dec 5;51(23):13938-13948. PMID: 29121463 -
Cell Commun Signal
Mitochondrial DNA release via mPTP and BAX/BAK drives inflammatory injury in intestinal ischemia reperfusion. [Abstract]2025 Dec 24;24(1):50. PMID: 41437056 -
Cell Commun Signal
IRF1 regulation of ZBP1 links mitochondrial DNA and chondrocyte damage in osteoarthritis. [Abstract]2024 Jul 18;22(1):366. PMID: 39026271 -
Phytomedicine
Lithospermic acid alleviates myocardial ischemia/reperfusion injury by inhibiting mitophagy via the Piezo1-PPP3/calcineurin-TFEB pathway. [Abstract]2025 Oct 11:148:157402. PMID: 41101069 -
Adv Healthc Mater
Adaptable Covalent Organic Framework-Hydrogel Microneedles for Glucose-Responsive Isoliquiritigenin Delivery in Diabetic Wound Therapy. [Abstract]2026 Jul;15(26):e71343. PMID: 42277632 -
Mater Today Bio
Ultrasound-driven microbubble motors for targeted myocardial ischemia-reperfusion injury treatment. [Abstract]2026 Jun 13:39:103349. PMID: 42368711 -
Mater Today Bio
Early-apoptotic membrane engineering of M2 macrophage-derived nanovesicles enables osteoimmunomodulatory bone repair. [Abstract]2026 Jun 8:38:103324. PMID: 42293395 -
-
Acta Pharmacol Sin
Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages. [Abstract]2025 Feb;46(2):430-447. PMID: 39223367 -
Arthritis Rheumatol
mTOR inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease. [Abstract]2023 Feb;75(2):305-317. PMID: 36057112 -
Biomater Res
Distinct Roles of Matrigel Enabled the Production of Expandable Hepatoblast and Polarized Hepatocyte Organoids from Human Embryonic Stem Cells under 3-Dimensional Suspension Conditions. [Abstract]2025 Nov 7:29:0280. PMID: 41209312 -
J Transl Med
MPTP mediated Ox-mtDNA release inducing macrophage pyroptosis and exacerbating MCD-induced MASH via promoting the ITPR3/Ca2+/NLRP3 pathway. [Abstract]2025 Nov 14;23(1):1289. PMID: 41239426 -
J Transl Med
Blockade of the mitochondrial DNA release ameliorates hepatic ischemia-reperfusion injury through avoiding the activation of cGAS-Sting pathway. [Abstract]2024 Aug 28;22(1):796. PMID: 39198913 -
Sci China Life Sci
Spinal segment-specific properties of neural stem cells contribute to the outcomes of spinal cord injury repair. [Abstract]2025 Aug 22. PMID: 40856925 -
Aging Dis
P-Glycoprotein Aggravates Blood Brain Barrier Dysfunction in Experimental Ischemic Stroke by Inhibiting Endothelial Autophagy. [Abstract]2022 Oct 1;13(5):1546-1561. PMID: 36186136
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Aging Dis. 2022 Oct 1;13(5):1546-1561. [Abstract]
Additionally, similar to P-gp siRNA silence, pharmacological inhibition of P-gp with Cyclosporine A (CsA; 22 mg/kg) significantly attenuates P-gp expression levels in ischemic brain as compared to vehicle treatment.
-
Proc Natl Acad Sci U S A
2021 Jan 12;118(2):e2009539118. PMID: 33376206
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2021 Jan 12;118(2):e2009539118. [Abstract]
Calcineurin activities of the PCE after FK506 or Cyclosporine A (CsA; 4 µM) treatment Zebrafish.
-
Oncogene
2024 Nov;43(49):3570-3585. PMID: 39402372 -
Cell Chem Biol
In vivo drug discovery for increasing incretin-expressing cells identifies DYRK inhibitors that reinforce the enteroendocrine system. [Abstract]2022 Sep 15;29(9):1368-1380.e5. PMID: 35998625 -
Int J Biol Macromol
Cordyceps militaris polysaccharide converts immunosuppressive macrophages into M1-like phenotype and activates T lymphocytes by inhibiting the PD-L1/PD-1 axis between TAMs and T lymphocytes. [Abstract]2020 May 1;150:261-280. PMID: 32044366 -
Int J Mol Med
Human papillomavirus E7 inhibits immune responses in keratinocytes by activating HTRA1‑mediated mitophagy. [Abstract]2026 Jan;57(1):22. PMID: 41235661 -
Neural Regen Res
Cyclophilin D-induced mitochondrial impairment confers axonal injury after intracerebral hemorrhage in mice. [Abstract]2023 Apr;18(4):849-855. PMID: 36204853 -
Int J Mol Med
TRAP1 attenuates H9C2 myocardial cell injury induced by extracellular acidification via the inhibition of MPTP opening. [Abstract]2020 Aug;46(2):663-674. PMID: 32626957 -
EMBO J
2023 Aug 15;42(16):e113258. PMID: 37409632 -
Antioxidants (Basel)
Reactive Oxygen Species Damage Bovine Endometrial Epithelial Cells via the Cytochrome C-mPTP Pathway. [Abstract]2023 Dec 16;12(12):2123. PMID: 38136242 -
Antioxidants (Basel)
Muscone and (+)-Borneol Cooperatively Strengthen CREB Induction of Claudin 5 in IL-1 β-Induced Endothelium Injury. [Abstract]2022 Jul 26;11(8):1455. PMID: 35892657 -
Free Radic Biol Med
Echinacoside improves antioxidant responses and angiogenesis through Parkin-MFN2-mediated mitophagy to promote diabetic wound healing. [Abstract]2026 Jul:250:436-452. PMID: 41962601 -
Free Radic Biol Med
LL37-induced mitochondrial stress activates the mtDNA/cGAS/STING pathway to promote mast cell-mediated rosacea inflammation. [Abstract]2025 Dec 18:244:422-434. PMID: 41421415 -
Free Radic Biol Med
Redox switch C674 in SERCA2 triggers Ca2+-calcineurin-MCU-Drp1 cascade and pulmonary vascular remodeling. [Abstract]2025 Dec 16:244:380-394. PMID: 41412527 -
Free Radic Biol Med
LINC03047 promotes mitophagy by recruiting hnRNPF to enhance CTGF mRNA stability in hypoxic pulmonary hypertension. [Abstract]2025 Nov 11:243:111-125. PMID: 41232621 -
-
Free Radic Biol Med
Calcineurin/NFAT1/Smad2 signaling regulates microglial autophagy that contributes to neuroinflammation and cognitive deficit in mice with sepsis-associated encephalopathy. [Abstract]2025 Aug 8:240:15-28. PMID: 40784585 -
Free Radic Biol Med
The tolerable upper intake level of manganese alleviates Parkinson-like motor performance and neuronal loss by activating mitophagy. [Abstract]2024 Nov 20:225:665-676. PMID: 39401732 -
Free Radic Biol Med
Exosomes derived from schwann cells alleviate mitochondrial dysfunction and necroptosis after spinal cord injury via AMPK signaling pathway-mediated mitophagy. [Abstract]2023 Nov 1:208:319-333. PMID: 37640169 -
Int J Pharm X
Ultrasound-targeted sirolimus-loaded microbubbles improves acute rejection of heart transplantation in rats by inhibiting TGF-β1-Smad signaling pathway, promoting autophagy and reducing inflammation. [Abstract]2024 Nov 4:8:100300. PMID: 39624342 -
Clin Transl Med
Translocation of gasdermin D induced mitochondrial injury and mitophagy mediated quality control in lipopolysaccharide related cardiomyocyte injury. [Abstract]2022 Aug;12(8):e1002. PMID: 36030524 -
Stem Cell Res Ther
hPSC-derived sacral neural crest cells restore erectile function in pelvic ganglia injury. [Abstract]2025 Oct 29;16(1):593. PMID: 41163062 -
Cell Rep
2026 Jun 25;45(7):117616. PMID: 42360879 -
Cell Rep
2026 Jun 9;45(6):117515. PMID: 42268710 -
Cell Rep
Aryl hydrocarbon receptor-induced activation of AIM2 inflammasome is mediated by MOMP and MPT: A vital therapeutic pathway for inflammation. [Abstract]2025 Dec 10;44(12):116673. PMID: 41385364 -
Cell Rep
Stem cell differentiation with consistent lineage commitment induced by a flash of ultrafast-laser activation in vitro and in vivo. [Abstract]2022 Mar 8;38(10):110486. PMID: 35263591 -
Cell Rep
Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer. [Abstract]2021 Nov 30;37(9):110069. PMID: 34852234
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Nov 30;37(9):110069. [Abstract]
Colony formation of CRC cells treated with Cyclosporine A (CsA; 2.5-5 μM) in combination with 5-FU or OXA for 48 h.
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Cell Rep. 2021 Nov 30;37(9):110069. [Abstract]
Immunoblotting analysis of indicated apoptotic markers expression in CRC cells treated with Cyclosporine A (CsA; 2.5-5 μM) in combination with 5-FU or OXA.
-
Cell Rep
Neuronal activity recruits the CRTC1/CREB axis to drive transcription-dependent autophagy for maintaining late-phase LTD. [Abstract]2021 Jul 20;36(3):109398. PMID: 34289350 -
Cell Prolif
Establishment of human corneal epithelial organoids for ex vivo modelling dry eye disease. [Abstract]2024 Jul 3:e13704. PMID: 38961590 -
Br J Pharmacol
A mitochondria-targeting and G-quadruplex structure-binding ligand inducing calcium overload and ferroptosis in human cancer cells. [Abstract]2025 Aug;182(16):3923-3951. PMID: 40344208 -
Br J Pharmacol
2021 Jun;178(11):2305-2323. PMID: 33591571
Cyclosporin A purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2021 Jun;178(11):2305-2323. [Abstract]
Smooth muscle cells are treated cyclosporin A (CsA, 1 μM) or PDTC (10 μM) for 24 h before measuring the activity of PPARγ2 promoter.
-
Chin Med
Aurantio-obtusin improves obesity and protects hepatic inflammation by rescuing mitochondrial damage in overwhelmed brown adipose tissue. [Abstract]2025 Mar 25;20(1):41. PMID: 40133913 -
J Med Chem
Discovery of Novel Purine Derivatives as Potent and Orally Bioavailable PGK1 Inhibitors for the Treatment of Inflammatory Bowel Disease. [Abstract]2025 Oct 23;68(20):21394-21411. PMID: 41077732 -
J Invest Dermatol
TAP2 Drives HLA-B∗13:01‒Linked Dapsone Hypersensitivity Syndrome Tolerance and Reactivity. [Abstract]2023 May;143(5):722-730.e1. PMID: 37306379 -
Redox Rep
Urolithin A alleviates vascular remodeling through mitochondrial SIRT3-mediated SOD2 deacetylation and antioxidation in hypertensive rats. [Abstract]2026 Dec;31(1):2622255. PMID: 41645805 -
J Ethnopharmacol
Tao-Hong-Si-Wu-Tang improves thioacetamide-induced liver fibrosis by reversing ACSL4-mediated lipid accumulation and promoting mitophagy. [Abstract]2024 Jun 13:118456. PMID: 38878839 -
J Agric Food Chem
Elevated PINK1/Parkin-Dependent Mitophagy and Boosted Mitochondrial Function Mediate Protection of HepG2 Cells from Excess Palmitic Acid by Hesperetin. [Abstract]2024 Jun 12;72(23):13039-13053. PMID: 38809522 -
J Agric Food Chem
Arsenic Exposure-Induced Acute Kidney Injury by Regulating SIRT1/PINK1/Mitophagy Axis in Mice and in HK-2 Cells. [Abstract]2023 Oct 25;71(42):15809-15820. PMID: 37843077 -
J Agric Food Chem
Apigenin Alleviated High-Fat-Diet-Induced Hepatic Pyroptosis by Mitophagy-ROS-CTSB-NLRP3 Pathway in Mice and AML12 Cells. [Abstract]2023 May 10;71(18):7032-7045. PMID: 37141464 -
Ecotoxicol Environ Saf
Platycodon grandifloras polysaccharides inhibit mitophagy injury induced by Cr (VI) in DF-1 cells. [Abstract]2020 Oct 1;202:110901. PMID: 32593805 -
Biochem Pharmacol
Upregulation of IL-37 in epithelial cells: A potential new mechanism of T cell inhibition induced by tacrolimus. [Abstract]2023 Oct:216:115796. PMID: 37690572 -
Biochem Pharmacol
Substitution of SERCA2 Cys674 aggravates cardiac fibrosis by promoting the transformation of cardiac fibroblasts to cardiac myofibroblasts. [Abstract]2022 Sep:203:115164. PMID: 35809651 -
Biochem Pharmacol
Insights gained from Single-Cell analysis of immune cells on Cyclosporine A treatment in autoimmune uveitis. [Abstract]2022 Aug:202:115116. PMID: 35671791 -
Biochem Pharmacol
Trehalose protects against cisplatin-induced cochlear hair cell damage by activating TFEB-mediated autophagy. [Abstract]2022 Mar:197:114904. PMID: 34971589 -
Life Sci
Oxytocin ameliorates cardiac hypertrophy by inhibiting mitochondrial dysfunction and pyroptosis via AMPK/PGC-1α /TFAM pathway. [Abstract]2026 Apr 15:391:124281. PMID: 41722768 -
Life Sci
Cyclophilin A inhibits trophoblast migration and invasion in vitro and vivo through p38/ERK/JNK pathways and causes features of preeclampsia in mice. [Abstract]2020 Nov 15;261:118351. PMID: 32858039 -
Inflamm Res
Quercetin and Kaempferol inhibit HMC-1 activation via SOCE/NFATc2 signaling and suppress hippocampal mast cell activation in lipopolysaccharide-induced depressive mice. [Abstract]2024 Jun;73(6):945-960. PMID: 38587532 -
J Mol Cell Biol
Depletion of Gsdma1/2/3 alleviates PMA-induced epidermal hyperplasia by inhibiting the EGFR-Stat3/Akt pathway. [Abstract]2024 Jul 1;16(1):mjad080. PMID: 38115633 -
Neurobiol Dis
Neonatal treatment with cyclosporine A restores neurogenesis and spinogenesis in the Ts65Dn model of Down syndrome. [Abstract]2019 Sep:129:44-55. PMID: 31085229 -
Colloids Surf B Biointerfaces
Ultrasound molecular imaging of antibody-mediated rejection with CD16a-targeted probes in a complement-independent pathway. [Abstract]2025 Oct 9:257:115197. PMID: 41076856 -
Commun Biol
Endoplasmic reticulum-mitochondria coupling prompts ZBP1-mediated RPE cell PANoptosis in age-related macular degeneration. [Abstract]2025 Jul 29;8(1):1118. PMID: 40731132 -
Front Microbiol
Ketoconazole induces reversible antifungal drug tolerance mediated by trisomy of chromosome R in Candida albicans. [Abstract]2024 Jul 30:15:1450557. PMID: 39139375 -
J Inflamm
Mitochondria protective and anti-apoptotic effects of peripheral benzodiazepine receptor and its ligands on the treatment of asthma in vitro and vivo. [Abstract]2024 Apr 19;21(1):11. PMID: 38641850 -
Eur J Pharmacol
MPTP controls the release of mtDNA and induces endothelial cell PANoptosis in trichloroethylene-induced immune kidney injury. [Abstract]2025 Oct 15:1005:178118. PMID: 40912515 -
Eur J Pharmacol
Salidroside attenuates CoCl2-simulated hypoxia injury in PC12 cells partly by mitochondrial protection. [Abstract]2021 Dec 5:912:174617. PMID: 34748770 -
Int J Mol Sci
Gsmtx4 Alleviated Osteoarthritis through Piezo1/Calcineurin/NFAT1 Signaling Axis under Excessive Mechanical Strain. [Abstract]2023 Feb 16;24(4):4022. PMID: 36835440 -
Int J Mol Sci
Metformin Alleviates Epirubicin-Induced Endothelial Impairment by Restoring Mitochondrial Homeostasis. [Abstract]2022 Dec 25;24(1):343. PMID: 36613786 -
Int Immunopharmacol
A systematic investigation on animal models of cyclosporine A combined with Escherichia coli to simulate the immunosuppressive status of sepsis patients before onset. [Abstract]2018 Sep:62:67-76. PMID: 29990696 -
-
Mol Neurobiol
Ginsenoside Rg1 Downregulates miR-9-5p Expression to Modulate SIRT1-Mediated Mitochondrial Dysfunction and Ameliorate Alzheimer's Disease. [Abstract]2025 Jun 6. PMID: 40478516 -
Mol Neurobiol
20-Deoxyingenol Activates Mitophagy Through TFEB and Promotes Functional Recovery After Spinal Cord Injury. [Abstract]2025 Jan;62(1):445-460. PMID: 38865079 -
Am J Respir Cell Mol Biol
High-Content Screening Identifies Cyclosporin A as a Novel ABCA3-Specific Molecular Corrector. [Abstract]2022 Apr;66(4):382-390. PMID: 34936540 -
Front Pharmacol
Schisandrin B Antagonizes Cardiotoxicity Induced by Pirarubicin by Inhibiting Mitochondrial Permeability Transition Pore (mPTP) Opening and Decreasing Cardiomyocyte Apoptosis. [Abstract]2021 Oct 15;12:733805. PMID: 34721023 -
Am J Respir Cell Mol Biol
Trametinib Attenuates Delayed Rejection and Preserves Thymic Function in Rat Lung Transplantation. [Abstract]2019 Sep;61(3):355-366. PMID: 30849233 -
Chem Biol Interact
Cyclophosphamide-induced iron homeostasis imbalance triggers ovarian toxicity through ferroptosis of ovarian granulosa cells in a mitophagy crosstalk manner. [Abstract]2026 Jun 1:432:112047. PMID: 41861985 -
Toxicology
In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]2025 Jun 3:154210. PMID: 40473197 -
Chem Biol Interact
Zn2+ regulates mitochondrial DNA efflux to inhibit AIM2-mediated ZBP1-PANoptosome pathway and alleviate septic myocardial injury. [Abstract]2025 May 8:111525. PMID: 40348119 -
J Thromb Haemost
Enhanced metabolic activation of and platelet response to clopidogrel in T-cell deficient mice through induction of Cyp2c and Cyp3a and inhibition of Ces1. [Abstract]2023 May;21(5):1322-1335. PMID: 36738827 -
Toxicology
PM2.5 induces mitochondrial dysfunction via AHR-mediated cyp1a1 overexpression during zebrafish heart development. [Abstract]2023 Mar 15:487:153466. PMID: 36841371 -
Chem Biol Interact
A pivotal role of selective autophagy in mitochondrial quality control: Implications for zinc oxide nanoparticles induced neurotoxicity. [Abstract]2022 Aug 25:363:110003. PMID: 35661739 -
Bioorg Chem
Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging. [Abstract]2022 Jun;123:105779. PMID: 35397430 -
Sci Rep
Mitigating cardiac allograft vasculopathy in a murine model via CD40-TRAF6 blockade and cyclosporin A synergy. [Abstract]2025 Jul 1;15(1):22327. PMID: 40595221 -
Toxics
2025 Apr 23;13(5):332. PMID: 40423411 -
PLoS Pathog
2024 Dec 2;20(12):e1012737. PMID: 39621796 -
J Dairy Sci
Whey protein hydrolysate alleviated acetaminophen-induced hepatocyte pyroptosis by activating mitophagy. [Abstract]2025 Aug;108(8):7896-7911. PMID: 40451585 -
Cell Signal
Inhibition of DJ-1 induces TFAM secretion from cancer cells to suppress tumor growth via promoting M1 macrophage polarization. [Abstract]2025 Mar 25:111765. PMID: 40147549 -
Mol Cell Biochem
Protective effect of astragaloside IV against zinc oxide nanoparticles induced human neuroblastoma SH-SY5Y cell death: a focus on mitochondrial quality control. [Abstract]2025 May;480(5):3079-3095. PMID: 39630360 -
J Cell Mol Med
Modelling the maternal-fetal interface: An in vitro approach to investigate nutrient and drug transport across the human placenta. [Abstract]2024 Oct;28(20):e70151. PMID: 39422159 -
J Physiol
A primary cell-based fluidic co-culture model to investigate drug transport across the human placenta. [Abstract]2026 Feb 26. PMID: 41746218 -
J Neurochem
MEC17-induced α-tubulin acetylation restores mitochondrial transport function and alleviates axonal injury after intracerebral hemorrhage in mice. [Abstract]2022 Jan;160(1):51-63. PMID: 34407220 -
Brain Res Bull
2025 Jan 16:111214. PMID: 39826756 -
iScience
GATA-4 overexpressing BMSC-derived exosomes suppress H/R-induced cardiomyocyte ferroptosis. [Abstract]2024 Aug 22;27(10):110784. PMID: 39391723 -
Brain Res Bull
Umbilical cord mesenchymal stem cell-conditioned medium inhibits microglial activation to ameliorate neuroinflammation in amyotrophic lateral sclerosis mice and cell models. [Abstract]2023 Oct 1:202:110760. PMID: 37704056 -
Acta Biochim Biophys Sin (Shanghai)
Induction of multiple subroutines of regulated necrosis in murine macrophages by natural BH3-mimetic gossypol. [Abstract]2022 Jan 25;54(1):64-76. PMID: 35130622 -
ACS Chem Neurosci
Short-Term Extremely Low-Frequency Electromagnetic Field Inhibits Synaptic Plasticity of Schaffer Collateral-CA1 Synapses in Rat Hippocampus via the Ca2+/Calcineurin Pathway. [Abstract]2021 Oct 6;12(19):3550-3557. PMID: 34498467 -
FASEB J
Penicillide Triggers Immunogenic Pyroptosis in Tumor Cells via Oxidative Stress/NF-κB/GSDMD Signaling Axis. [Abstract]2026 Mar 31;40(6):e71636. PMID: 41842655 -
FASEB J
ORAI3 Modulates Oral Squamous Cell Carcinoma Metastasis Through the Ca2+/Calmodulin/Calcineurin/ETV4 Signaling Pathway. [Abstract]2025 Dec 31;39(24):e71322. PMID: 41417281 -
FEBS J
Oxaliplatin accelerates immunogenic cell death by activating the cGAS/STING/TBK1/IRF5 pathway in gastric cancer. [Abstract]2025 Apr 22. PMID: 40260556 -
J Virol
2024 Nov 19;98(11):e0094724. PMID: 39480090 -
Virol J
Cytomegalovirus infection initiates inflammatory bowel disease by activating a positive MyD88/NF-κB feedback loop in allogeneic skin transplantation mice. [Abstract]2025 Apr 16;22(1):101. PMID: 40241182 -
Naunyn Schmiedebergs Arch Pharmacol
Kaempferol attenuates cyclosporine-induced renal tubular injury via inhibiting the ROS-ASK1-MAPK pathway. [Abstract]2025 Mar;398(3):3001-3014. PMID: 39316086 -
J Immunol
IL-2 Signaling Couples the MAPK and mTORC1 Axes to Promote T Cell Proliferation and Differentiation in Teleosts. [Abstract]2022 Apr 1;208(7):1616-1631. PMID: 35321881 -
J Immunol
Ca2+-Calcineurin Axis-Controlled NFAT Nuclear Translocation Is Crucial for Optimal T Cell Immunity in an Early Vertebrate. [Abstract]2020 Feb 1;204(3):569-585. PMID: 31871019 -
Toxins
2019 Jun 18;11(6):349. PMID: 31216655 -
-
Neurotox Res
Apelin-36 Protects HT22 Cells Against Oxygen-Glucose Deprivation/Reperfusion-Induced Oxidative Stress and Mitochondrial Dysfunction by Promoting SIRT1-Mediated PINK1/Parkin-Dependent Mitophagy. [Abstract]2021 Jun;39(3):740-753. PMID: 33580874 -
Vet Res
Residue 188 of the Hexon protein governs FAdV-4 pathogenicity by activating PINK1/Parkin-mediated mitophagy. [Abstract]2026 Jun 13;57(1):107. PMID: 42288922 -
ESC Heart Fail
Inhibition of adenosine kinase alleviates hypertrophic cardiomyopathy by ameliorating coronary microvascular dysfunction. [Abstract]2026 May 5;13(3):xvag118. PMID: 42015547 -
Viruses
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). [Abstract]2020 Jun 10;12(6):628. PMID: 32532085 -
Biochim Biophys Acta Mol Cell Biol Lipids
Macrophage iron retention aggravates atherosclerosis: Evidence for the role of autocrine formation of hepcidin in plaque macrophages. [Abstract]2020 Feb;1865(2):158531. PMID: 31666189 -
Mol Immunol
Gelatin enhances bacteria-phagocytosis via a ROS-mitochondria-STING axis in differentiated human macrophage-like U937 cells. [Abstract]2025 Oct:186:48-62. PMID: 40815890 -
Drug Metab Dispos
Activation of pregnane X receptor-organic anion transporting polypeptide 1a/b /P-glycoprotein/multidrug resistance protein 2 axis mediates the accelerated blood and liver clearance of PEGylated liposomes. [Abstract]2025 Nov;53(11):100172. PMID: 41106060 -
Drug Metab Dispos
Unveiling hepatic Krüppel-like factor 15 as the key regulator of cyclosporine A metabolism and adverse effects. [Abstract]2025 Jul 29;53(9):100136. PMID: 40885107 -
Drug Metab Dispos
Identification of selective substrates and inhibitors of the major human renal uptake transporters. [Abstract]2025 Mar;53(3):100046. PMID: 40024137 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
-
Exp Cell Res
2024 Jul 31;441(2):114182. PMID: 39094903 -
Arch Biochem Biophys
Silibinin alleviates ferroptosis of rat islet β cell INS-1 induced by the treatment with palmitic acid and high glucose through enhancing PINK1/parkin-mediated mitophagy. [Abstract]2023 Jul 15:743:109644. PMID: 37245586 -
J Neurooncol
Single-cell RNA-seq reveals diverse molecular signatures associated with Methotrexate resistance in primary central nervous system lymphoma cells. [Abstract]2025 Mar;172(1):163-173. PMID: 39636551 -
Phytochemistry
Immunosuppressive gentianellane-type sesterterpenoids from the traditional Uighur medicine Gentianella turkestanorum. [Abstract]2021 Jul:187:112780. PMID: 33915419 -
Neuroscience
Trichostatin A-primed spinal cord organoids alleviate oxidative stress and improve recovery after spinal cord injury involving the NRF2/HO-1 signaling pathway. [Abstract]2026 Jun 6:610:122-135. PMID: 42250855 -
Int J Cardiol
Kirenol attenuates pressure overload-induced heart failure by enhancing autophagy in macrophages. [Abstract]2025 Dec 1:440:133681. PMID: 40752803 -
Food Chem Toxicol
2024 Apr:186:114522. PMID: 38373586 -
Food Chem Toxicol
Alliin alleviates LPS-induced pyroptosis via promoting mitophagy in THP-1 macrophages and mice. [Abstract]2022 Feb:160:112811. PMID: 34999177 -
Kaohsiung J Med Sci
Melatonin Exerts Chondroprotective Effects Against Osteoarthritis by Promoting PI3K/AKT/FoxO3-Mediated Mitophagy. [Abstract]2025 Nov 5:e70131. PMID: 41190713 -
BMC Cardiovasc Disord
Calcineurin/NFATc3 pathway mediates myocardial fibrosis in diabetes by impairing enhancer of zeste homolog 2 of cardiac fibroblasts. [Abstract]2023 Sep 21;23(1):474. PMID: 37735624 -
Placenta
Cyclosporin A alleviates trophoblast apoptosis and senescence by promoting autophagy in preeclampsia. [Abstract]2022 Jan:117:95-108. PMID: 34785431 -
Cell Biochem Biophys
Downregulation of IGFBP7 Alleviates LPS-induced Inflammation and Apoptosis in WI-38 Cells via Enhancing Mitophagy. [Abstract]2025 Jun;83(2):1565-1573. PMID: 39347911 -
Vet Microbiol
Cytopathic BVDV engages VDAC1 through NS3 to trigger mitochondrial permeability transition-dependent intrinsic apoptosis. [Abstract]2026 Aug:319:111069. PMID: 42139791 -
Toxicol In Vitro
Clarify the potential cholestatic hepatotoxicity components from Chinese Herb Medicine and metabolism's role via hBSEP vesicles and S9/hBSEP vesicles. [Abstract]2022 Apr:80:105324. PMID: 35101544 -
Biochem Biophys Res Commun
Host defense peptide Hymenochirin-1B induces lung cancer cell apoptosis and cell cycle arrest through the mitochondrial pathway. [Abstract]2019 Apr 30;512(2):269-275. PMID: 30885438 -
Biochem Biophys Res Commun
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. [Abstract]2018 Sep 3;503(1):297-303. PMID: 29890135 -
J Viral Hepat
The Differential Effects of Immunosuppressants on Hepatitis E Virus Replication and the Triggered Inflammatory Responses in Macrophages. [Abstract]2026 Jan;33(1):e70118. PMID: 41400072 -
Exp Ther Med
PROSER2 is a poor prognostic biomarker for patients with osteosarcoma and promotes proliferation, migration and invasion of osteosarcoma cells. [Abstract]2022 Nov 8;24(6):750. PMID: 36561964 -
Biopharm Drug Dispos
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells. [Abstract]2022 Dec;43(6):265-271. PMID: 36195987 -
Genes Genomics
2022 Dec;44(12):1593-1605. PMID: 35666459 -
Connect Tissue Res
Collagen I alleviates UVB-induced oxidative DNA damage and inhibits YAP-p73 apoptotic pathway in human keratinocytes HaCaT. [Abstract]2026 May;67(3):243-257. PMID: 41700367 -
Biochem Genet
Increased GABBR2 Expression on Cell Membranes Causes Increased Ca2 + Inward Flow, Associated with Cognitive Impairment in Early Alzheimer's Disease. [Abstract]2024 Dec 26. PMID: 39724481 -
Am J Transl Res
Anesthesia and surgery induce delirium-like behavior in susceptible mice: the role of oxidative stress. [Abstract]2018 Aug 15;10(8):2435-2444. PMID: 30210682 -
Acta Cir Bras
Protective effect of hydroxysafflor yellow A on cyclosporin A-induced renal oxidative stress in vitro and in vivo. [Abstract]2022 Jun 15;37(3):e370305. PMID: 35730865 -
STAR Protoc
A cellular thermal shift assay for detecting amino acid sites involved in drug target engagement. [Abstract]2022 Jun 4;3(2):101423. PMID: 35677609 -
Mol Cell Toxicol (2019) 15:209-219
-
bioRxiv
Citrate Compartmentalization Controls Calcium-Dependent Cytokine Production in Effector T Cells. [Abstract]2026 Jun 12:2026.06.11.731694. PMID: 42327233 -
bioRxiv
2026 May 29:2026.05.26.727520. PMID: 42244578 -
-
-
-
Sci Total Environ
Voltage-dependent anion channel 1 mediates mitochondrial fission and glucose metabolic reprogramming in response to ionizing radiation. [Abstract]2024 Jun 30:946:174246. PMID: 38955266 -
Elife
Sustained store-operated calcium entry utilizing activated chromatin state leads to instability in iTregs. [Abstract]2023 Dec 6:12:RP88874. PMID: 38055613 -
-
-
-
-
Chemosphere
Regulation of Cx43 and its role in trichloroethylene-induced cardiac toxicity in H9C2 rat cardiomyocytes. [Abstract]2023 May:323:138249. PMID: 36842555 -
-
Oxid Med Cell Longev
SIRT3-Mediated CypD-K166 Deacetylation Alleviates Neuropathic Pain by Improving Mitochondrial Dysfunction and Inhibiting Oxidative Stress. [Abstract]2022 Sep 1;2022:4722647. PMID: 36092157 -
Research (Wash D C)
CNS Organoid Surpasses Cell-Laden Microgel Assembly to Promote Spinal Cord Injury Repair. [Abstract]2022 Aug 3:2022:9832128. PMID: 36061824 -
Biomed Pharmacother
Curcumin exerts chondroprotective effects against osteoarthritis by promoting AMPK/PINK1/Parkin-mediated mitophagy. [Abstract]2022 May 10;151:113092. PMID: 35550528 -
Front Med
Resveratrol promotes the survival and neuronal differentiation of hypoxia-conditioned neuronal progenitor cells in rats with cerebral ischemia. [Abstract]2021 Jun;15(3):472-485. PMID: 33263836 -
Ann Transl Med
Artesunate exerts anti-prolactinoma activity by inhibiting mitochondrial metabolism and inducing apoptosis. [Abstract]2020 Jul;8(14):858. PMID: 32793702 -
-
-
-
J Clin Toxicol 2014, 4:5
Solvant et solubilité
DMSO : 62.5 mg/mL (51.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 50 mg/mL (41.58 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (1.73 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Immunosuppressive agents are dissolved in ethanol at concentrations 1000-fold more than the concentration desired for cell treatments. Cells (106) are suspended in 1 mL of complete medium in microcentrifuge tubes; 1 μL of ethanol or of the ethanolic solution of Cyclosporin A is added, and the cells are incubated at 37°C for 1 hr. Cells are washed twice with 1 mL of PBS on ice and lysed in 50 μL of hypotonic buffer containing 50 mM Tris (pH 7.5); 0.1 mM EGTA; 1 mM EDTA; 0.5 mM dithiothreitol; and 50 μg of phenylmethylsulfonyl fluoride, 50 μg of soybean trypsin inhibitor, 5 μg of leupeptin, and 5 μg of Kiker 52G per mL. Lysates are subjected to three cycles of freezing in liquid nitrogen followed by thawing at 30°C and then are centrifuged at 4°C for 10 min at 12,000×g.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Rats are immunized on day 0 i.p. with 0 5 mL and mice i.v. with 0 2 mL of a 10% suspension of washed sheep erythrocytes (SE). To elicit a secondary response, mice are boosted 8-11 weeks after the primary immunization with an i.v. injection of 0-2 mL of 0 25% washed SE (107 cells). For prolonged treatment the animals receive on the average 45 mg/kg cyclosporin A daily in the food during 13 weeks. These rats are immunized 5 days before killing.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (294 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Handschumacher RE, et al. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984 Nov 2;226(4674):544-7. [Content Brief]
[2]. Liu J, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991 Aug 23;66(4):807-15. [Content Brief]
[3]. Fruman DA, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3686-90. [Content Brief]
[4]. Flanagan WM, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991 Aug 29;352(6338):803-7. [Content Brief]
[5]. Nicolli A, et al. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, and cyclosporin A-sensitive channel. J Biol Chem. 1996 Jan 26;271(4):2185-92. [Content Brief]
[6]. Borel JF, et al. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977 Jun;32(6):1017-25. [Content Brief]
[7]. Williams, R, et al. Randomised trial comparing FK506 and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet, 1994, 344(8920), 423-428. [Content Brief]
[8]. Dalmarco EM, et al. Cyclosporin A inhibits CD11a/CD18 adhesion molecules due to inhibition of TNFalpha and IL-1 beta levels in the mouse model of pleurisy induced by carrageenan. Cell Adh Migr. 2008 Oct-Dec;2(4):231-5. [Content Brief]
[9]. Medeiros M, et al. Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. Can J Physiol Pharmacol. 2007 May;85(5):502-6. [Content Brief]
[10]. Nguyen LT, et al. Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse. Sci Rep. 2021 Jun 14;11(1):12437. [Content Brief]
[11]. Ling H, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol. 2003 Feb;14(2):377-88. [Content Brief]
[12]. Soini L, et al. Molecular glues to stabilise protein-protein interactions. Curr Opin Chem Biol. 2022 Aug;69:102169. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 0.8315 mL | 4.1576 mL | 8.3152 mL | 20.7881 mL |
| 5 mM | 0.1663 mL | 0.8315 mL | 1.6630 mL | 4.1576 mL | |
| 10 mM | 0.0832 mL | 0.4158 mL | 0.8315 mL | 2.0788 mL | |
| 15 mM | 0.0554 mL | 0.2772 mL | 0.5543 mL | 1.3859 mL | |
| 20 mM | 0.0416 mL | 0.2079 mL | 0.4158 mL | 1.0394 mL | |
| 25 mM | 0.0333 mL | 0.1663 mL | 0.3326 mL | 0.8315 mL | |
| 30 mM | 0.0277 mL | 0.1386 mL | 0.2772 mL | 0.6929 mL | |
| 40 mM | 0.0208 mL | 0.1039 mL | 0.2079 mL | 0.5197 mL | |
| DMSO | 50 mM | 0.0166 mL | 0.0832 mL | 0.1663 mL | 0.4158 mL |